Referências Técnicas & Científicas

CoproOne® Disbiose

Zonulina Fecal
1. FASANO, A.; NOT, T.; WANG, W.; UZZAU, S.; BERTI, I.; TOMMASINI, A.; GOLDBLUM, S. E. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. The Lancet, v. 355, n. 9214, p. 1518–1519, 2000. DOI: 10.1016/S0140-6736(00)02169-3. PMID: 10770304.
2. WANG, W.; UZZAU, S.; GOLDBLUM, S. E.; FASANO, A. Human zonulin, a potential modulator of intestinal tight junctions. Journal of Cell Science, v. 113, pt. 24, p. 4435–4440, 2000. PMID: 11082037.
3. FASANO, A. Intestinal zonulin: open sesame! Gut, v. 49, n. 2, p. 159–162, 2001. DOI: 10.1136/gut.49.2.159. PMID: 11454779.
4. WATTS, T.; BERTI, I.; SAPONE, A.; GERARDUZZI, T.; NOT, T.; ZIELKE, R.; FASANO, A. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proceedings of the National Academy of Sciences of the United States of America (PNAS), v. 102, n. 8, p. 2916–2921, 2005. DOI: 10.1073/pnas.0500178102. PMID: 15710870.
5. SAPONE, A.; DE MAGISTRIS, L.; PIETZAK, M.; CLEMENTE, M. G.; TRIPATHI, A.; CUCCA, F.; LAMPIS, R. et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes, v. 55, n. 5, p. 1443–1449, 2006. DOI: 10.2337/db05-1584. PMID: 16644703.
6. THOMAS, K. E.; SAPONE, A.; FASANO, A.; VOGEL, S. N. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in celiac disease. Journal of Immunology, v. 176, n. 4, p. 2512–2521, 2006. DOI: 10.4049/jimmunol.176.4.2512. PMID: 16456012.
7. STENMAN, L. K.; HOLMSTRÖM, K.; AXLING, U.; KROGIUS-KURKIVIITA, A.; FÄRKKILÄ, M.; LAHTI, L.; FAZIO, V. et al. Increased intestinal permeability correlates with serum zonulin but not with plasma lipopolysaccharides in obese humans. Metabolism: Clinical and Experimental, v. 65, n. 11, p. 1747–1756, 2016. DOI: 10.1016/j.metabol.2016.09.011. PMID: 27908552.
8. MORETTI, D.; GAO, X.; PLEBANI, M.; FASANO, A. The role of zonulin in celiac disease and type 1 diabetes: time for a critical reappraisal. Digestive and Liver Disease, v. 53, n. 12, p. 1530–1537, 2021. DOI: 10.1016/j.dld.2021.09.001. PMID: 34598748.

Histamina Fecal
1. BARCIK, W.; WAWRZYNIAK, M.; AKDIS, C. A.; O’MAHONY, L. Immune regulation by histamine and histamine-secreting bacteria. Current Opinion in Immunology, v. 48, p. 108–113, 2017. DOI: 10.1016/j.coi.2017.08.014.
2. SMOLINSKA, S.; JUTEL, M.; CRAMERI, R.; O’MAHONY, L. Histamine and gut mucosal immune regulation. Allergy, v. 69, n. 3, p. 273–281, 2014. DOI: 10.1111/all.12330.
3. KOVACOVA-HANUSKOVA, E.; BUDAY, T.; GAVLIAKOVA, S.; PLEVKOVA, J. Histamine, histamine intoxication and intolerance. Allergologia et Immunopathologia (Madrid), v. 43, n. 5, p. 498–506, 2015. DOI: 10.1016/j.aller.2015.05.001.
4. NEUHUBER, W.; WÖRL, J. Monoamines in the enteric nervous system. Histochemistry and Cell Biology, v. 150, n. 6, p. 703–709, 2018. DOI: 10.1007/s00418-018-1723-4.
5. TOKITA, Y.; AKIHO, H.; NAKAMURA, K.; IHARA, E.; YAMAMOTO, M. Contraction of gut smooth muscle cells assessed by fluorescence imaging. Journal of Pharmacological Sciences, v. 127, n. 3, p. 344–351, 2015. DOI: 10.1016/j.jphs.2015.01.006.
6. POTTS, R. A.; TIFFANY, C. M.; PAKPOUR, N.; LOKKEN, K. L.; TIFFANY, C. R.; CHEUNG, K.; TSOLIS, R. M.; LUCKHART, S. Mast cells and histamine alter intestinal permeability during malaria parasite infection. Immunobiology, v. 221, n. 3, p. 468–474, 2016. DOI: 10.1016/j.imbio.2015.11.007.
7. FABISIAK, A.; WŁODARCZYK, J.; FABISIAK, N.; STORR, M.; FICHNA, J. Targeting histamine receptors in irritable bowel syndrome: a critical appraisal. Journal of Neurogastroenterology and Motility, v. 23, n. 3, p. 341–348, 2017. DOI: 10.5056/jnm16090.
8. NAM, Y.; MIN, Y. S.; SOHN, U. D. Recent advances in pharmacological research on the management of irritable bowel syndrome. Archives of Pharmacal Research, v. 41, n. 9, p. 955–966, 2018. DOI: 10.1007/s12272-018-1059-7.
9. BARBARA, G.; WANG, B.; STANGHELLINI, V.; DE GIORGIO, R.; CREMON, C.; DI NARDO, G.; TREVISANI, M.; CAMPI, B.; GEPPETTI, P.; TONINI, M.; et al. Mast cell-dependent excitation of visceral nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology, v. 132, n. 1, p. 26–37, 2007. DOI: 10.1053/j.gastro.2006.10.030.
10. GALLARDO, P.; IZQUIERDO, M.; VIDAL, R. M.; SOTO, F.; OSSA, J. C.; FARFAN, M. J. Gut microbiota–metabolome changes in children with diarrhea by diarrheagenic E. coli. Frontiers in Cellular and Infection Microbiology, v. 10, n. 485, p. 1–10, 2020. DOI: 10.3389/fcimb.2020.00485.
11. MCINTOSH, K.; REED, D. E.; SCHNEIDER, T.; DANG, F.; KESHTELI, A. H.; DE PALMA, G.; MADSEN, K.; BERCIK, P.; VANNER, S. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut, v. 66, n. 7, p. 1241–1251, 2017. DOI: 10.1136/gutjnl-2015-311339.
12. NEREE, A. T.; SORET, R.; MARCOCCI, L.; PIETRANGELI, P.; PILON, N.; MATEESCU, M. A. Vegetal diamine oxidase alleviates histamine-induced contraction of colonic muscles. Scientific Reports, v. 10, n. 21563, p. 1–9, 2020. DOI: 10.1038/s41598-020-78134-3.
13. CAMILLERI, M.; BOECKXSTAENS, G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut, v. 66, n. 5, p. 966–974, 2017. DOI: 10.1136/gutjnl-2016-313425.
14. BARCIK, W.; PUGIN, B.; BRESCÓ, M. S.; WESTERMANN, P.; RINALDI, A.; GROEGER, D.; VAN ELST, D.; SOKOLOWSKA, M.; KRAWCZYK, K.; FREI, R.; et al. Bacterial secretion of histamine within the gut influences immune responses within the lung. Allergy, v. 74, n. 5, p. 899–909, 2019. DOI: 10.1111/all.13660.
15. SCHINK, M.; KONTUREK, P. C.; TIETZ, E.; et al. Microbial patterns in patients with histamine intolerance. Journal of Physiology and Pharmacology, v. 69, n. 4, p. 579–593, 2018. DOI: 10.26402/jpp.2018.4.09.
16. CHOI, I. Y.; KIM, J.; KIM, S. H.; BAN, O. H.; YANG, J.; PARK, M. K. Safety evaluation of Bifidobacterium breve IDCC4401 isolated from infant feces for use as a commercial probiotic. Journal of Microbiology and Biotechnology, v. 31, n. 7, p. 949–955, 2021. DOI: 10.4014/jmb.2103.03041.
17. SHARIKADZE, O.; ZUBCHENKO, S.; MARUNIAK, S.; YURIEV, S. Investigation of protective effects of synbiotics on allergopathy formation. Georgian Medical News, n. 280–281, p. 90–94, 2018. PMID: 30173449.
18. PITHVA, S.; SHEKH, S.; DAVE, J.; VYAS, B. R. M. Probiotic attributes of autochthonous Lactobacillus rhamnosus strains of human origin. Applied Biochemistry and Biotechnology, v. 173, n. 1, p. 259–277, 2014. DOI: 10.1007/s12010-014-0839-9.

Calprotectina Fecal
1. D’HAENS, G. et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflammatory Bowel Diseases, v. 18, n. 12, p. 2218–2224, 2012. DOI: 10.1002/ibd.22917. PMID: 22344985.
2. FAGERBERG, U. L.; LÖÖF, L.; MERZOUG, R. D.; HANSSON, L.-O.; FINKEL, Y. Fecal calprotectin levels in healthy children studied with an improved assay. Journal of Pediatric Gastroenterology and Nutrition, v. 37, n. 4, p. 468–472, 2003. DOI: 10.1097/00005176-200310000-00021. PMID: 14508215.
3. FAGERHOL, M. K. Calprotectin, a faecal marker of organic gastrointestinal abnormality. The Lancet, v. 356, n. 9244, p. 1783–1784, 2000. DOI: 10.1016/S0140-6736(00)03215-7. PMID: 11117921.
4. HESTVIK, E. et al. Faecal calprotectin concentrations in apparently healthy children aged 0–12 years in urban Kampala, Uganda: a community-based survey. BMC Pediatrics, v. 11, n. 9, p. 1–8, 2011. DOI: 10.1186/1471-2431-11-9. PMID: 21284861.
5. KONIKOFF, M. R.; DENSON, L. A. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflammatory Bowel Diseases, v. 12, n. 6, p. 524–534, 2006. DOI: 10.1097/00054725-200606000-00006. PMID: 16775498.
6. POULLIS, A.; FOSTER, R.; NORTHFIELD, T. C.; MENDALL, M. A. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, v. 16, n. 4, p. 675–681, 2002. DOI: 10.1046/j.1365-2036.2002.01208.x. PMID: 11929378.
7. TIBBLE, J. et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut, v. 47, n. 4, p. 506–513, 2000. DOI: 10.1136/gut.47.4.506. PMID: 10986208.
8. TIBBLE, J. A.; SIGTHORSSON, G.; BRIDGER, S.; FAGERHOL, M. K.; BJARNASON, I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology, v. 119, n. 1, p. 15–22, 2000. DOI: 10.1053/gast.2000.8523. PMID: 10889150.
9. TØN, H. et al. Improved assay for fecal calprotectin. Clinica Chimica Acta, v. 292, n. 1–2, p. 41–54, 2000. DOI: 10.1016/S0009-8981(99)00219-0. PMID: 10727677.
10. VAN RHEENEN, P. F.; VAN DE VIJVER, E.; FIDLER, V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ, v. 341, c3369, p. 1–9, 2010. DOI: 10.1136/bmj.c3369. PMID: 20634346.
11. CHEN, C.-C.; HUANG, J.-L.; CHANG, C.-J.; KONG, M.-S. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. Journal of Pediatric Gastroenterology and Nutrition, v. 55, n. 5, p. 541–547, 2012. DOI: 10.1097/MPG.0b013e31825c4b12. PMID: 22499061.
12. LANGHORST, J. et al. Non-invasive Marker der Entzündungsaktivität bei Patienten mit chronisch entzündlichen Darmerkrankungen (CED): Vergleich von Lactoferrin, Calprotectin, PMN-Elastase im Stuhl, Serum-CRP und klinischen Aktivitätsindizes. Zeitschrift für Gastroenterologie, v. 45, P261, 2007. PMID: 17611906.
13. SCHRÖDER, O.; NAUMANN, M.; SHASTRI, Y.; POVSE, N.; STEIN, J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Alimentary Pharmacology & Therapeutics, v. 26, n. 7, p. 1035–1042, 2007. DOI: 10.1111/j.1365-2036.2007.03450.x. PMID: 17767476.

Lactoferrina Fecal
1. LEVAY, P. F.; VILJOEN, M. Lactoferrin: a general review. Haematologica, v. 80, n. 3, p. 252–267, 1995. PMID: 7672727.
2. GISBERT, J. P.; McNICHOLL, A. G.; GOMOLLON, F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflammatory Bowel Diseases, v. 15, n. 12, p. 1746–1754, 2009. DOI: 10.1002/ibd.20934. PMID: 19637370.
3. UCHIDA, K.; MATSUSE, R.; TOMITA, S.; SUGI, K.; SAITOH, O.; OHSHIBA, S. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clinical Biochemistry, v. 27, n. 4, p. 259–264, 1994. DOI: 10.1016/0009-9120(94)90027-2. PMID: 8001286.
4. HAYAKAWA, T.; JIN, C. X.; KO, S. B.; KITAGAWA, M.; ISHIGURO, H. Lactoferrin in gastrointestinal disease. Internal Medicine, v. 48, n. 15, p. 1251–1254, 2009. DOI: 10.2169/internalmedicine.48.2199. PMID: 19652425.
5. LANGHORST, J.; BOONE, J. Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases. Drugs of Today (Barcelona), v. 48, n. 2, p. 149–161, 2012. DOI: 10.1358/dot.2012.48.2.1732555. PMID: 22384454.
6. ABRAHAM, B. P.; KANE, S. Fecal markers: calprotectin and lactoferrin. Gastroenterology Clinics of North America, v. 41, n. 2, p. 483–495, 2012. DOI: 10.1016/j.gtc.2012.01.007. PMID: 22500530.
7. MOSLI, M. H.; ZOU, G.; GARG, S. K.; FEAGAN, S. G.; MacDONALD, J. K.; CHANDE, N.; SANDBORN, W. J.; FEAGAN, B. G. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. American Journal of Gastroenterology, v. 110, n. 6, p. 802–819, 2015. DOI: 10.1038/ajg.2015.120. PMID: 25964225.

Alfa-1 Antitripsina Fecal
1. AMARRI, S. et al. Changes of gut microbiota and immune markers during the complementary feeding period in healthy breast-fed infants. Journal of Pediatric Gastroenterology and Nutrition, v. 42, n. 5, p. 488–495, 2006. DOI: 10.1097/01.mpg.0000221897.19743.0b. PMID: 16641581.
2. FAUST, D. et al. Determination of alpha1-proteinase inhibitor by a new enzyme-linked immunosorbent assay in feces, serum and an enterocyte-like cell line. Zeitschrift für Gastroenterologie, v. 39, n. 9, p. 769–774, 2001. PMID: 11605363.
3. FAUST, D. et al. Regulation of alpha1-proteinase inhibitor release by pro-inflammatory cytokines in human intestinal epithelial cells. Clinical and Experimental Immunology, v. 128, n. 2, p. 279–284, 2002. DOI: 10.1046/j.1365-2249.2002.01824.x. PMID: 11966767.
4. HSU, P.-I. et al. Diagnosis of gastric malignancy using gastric juice alpha1-antitrypsin. Cancer Epidemiology, Biomarkers & Prevention, v. 19, n. 2, p. 405–411, 2010. DOI: 10.1158/1055-9965.EPI-09-0662. PMID: 20142232.
5. LAMPRECHT, M. et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men: a randomized, double-blinded, placebo-controlled trial. Journal of the International Society of Sports Nutrition, v. 9, n. 1, p. 45, 2012. DOI: 10.1186/1550-2783-9-45. PMID: 23107338.
6. MUSS, C.; SCHÜTZ, B.; KIRKAMM, R. Alpha-1-Antitrypsin – ein objektiver Verlaufsparameter bei entzündlichen Darmerkrankungen. Ärztezeitschrift für Naturheilverfahren, v. 43, n. 4, 2002.
7. OSWARI, H. et al. Comparison of stool microbiota compositions, stool alpha1-antitrypsin and calprotectin concentrations, and diarrhoeal morbidity of Indonesian infants fed breast milk or probiotic/prebiotic-supplemented formula. Journal of Paediatrics and Child Health, v. 49, n. 12, p. 1032–1039, 2013. DOI: 10.1111/jpc.12303. PMID: 23937344.
8. QUINT, J. K. et al. SERPINA1 11478G>A variant, serum α1-antitrypsin, exacerbation frequency and FEV1 decline in COPD. Thorax, v. 66, n. 5, p. 418–424, 2011. DOI: 10.1136/thx.2010.149989. PMID: 21317287.
9. RAGAB, H. M. et al. Clinical utility of serum TNF-α and alpha-1 antitrypsin in predicting the stage and progression of lung cancer. International Journal of Integrative Biology, v. 7, n. 1, p. 45–52, 2009.
10. ROECKEL, N. et al. High frequency of LMAN1 abnormalities in colorectal tumors with microsatellite instability. Cancer Research, v. 69, n. 1, p. 292–299, 2009. DOI: 10.1158/0008-5472.CAN-08-2551. PMID: 19117995.
11. STRYGLER, B. et al. α1-Antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology, v. 99, n. 5, p. 1380–1387, 1990. DOI: 10.1016/0016-5085(90)91159-C. PMID: 2227275.
12. TÖRÖK, E. et al. Primary human hepatocytes on biodegradable poly(L-lactic acid) matrices: a promising model for improving transplantation efficiency with tissue engineering. Liver Transplantation, v. 17, n. 2, p. 104–114, 2011. DOI: 10.1002/lt.22201. PMID: 21280177.

Elastase Pancreática
1. NANDHAKUMAR, N.; GREEN, M. R. Interpretations: how to use faecal elastase testing. Archives of Disease in Childhood. Education and Practice Edition, v. 95, n. 4, p. 119–123, 2010. DOI: 10.1136/adc.2009.173187. PMID: 20581338.
2. WHITCOMB, D. C.; LOWE, M. E. Human pancreatic digestive enzymes. Digestive Diseases and Sciences, v. 52, n. 1, p. 1–17, 2007. DOI: 10.1007/s10620-006-9589-z. PMID: 17205399.
3. DOMINICI, R.; FRANZINI, C. Fecal elastase-1 as a test for pancreatic function: a review. Clinical Chemistry and Laboratory Medicine (CCLM), v. 40, n. 4, p. 325–332, 2002. DOI: 10.1515/CCLM.2002.051. PMID: 12059069.
4. LÖSER, C.; MÖLLGAARD, A.; FÖLSCH, U. R. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut, v. 39, n. 4, p. 580–586, 1996. DOI: 10.1136/gut.39.4.580. PMID: 8944569.
5. STEIN, J.; KRUGER, E.; SPENGLER, U.; LÖSER, C.; WEITZEL, U.; FÖLSCH, U. R. Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Clinical Chemistry, v. 42, n. 2, p. 222–226, 1996. PMID: 8595719.
6. DOMÍNGUEZ-MUÑOZ, J. E.; HARDT, P. D.; LERCH, M. M.; LÖHR, M. J. Potential for screening for pancreatic exocrine insufficiency using the fecal elastase-1 test. Digestive Diseases and Sciences, v. 62, n. 5, p. 1119–1130, 2017. DOI: 10.1007/s10620-017-4524-z. PMID: 28315028.
7. DE LA IGLESIA, D.; AGUDO-CASTILLO, B.; GALEGO-FERNÁNDEZ, M.; RAMA-FERNÁNDEZ, A.; DOMÍNGUEZ-MUÑOZ, J. E. Diagnostic accuracy of fecal elastase-1 test for pancreatic exocrine insufficiency: a systematic review and meta-analysis. United European Gastroenterology Journal, v. 13, n. 8, p. 1571–1582, 2025. DOI: 10.1002/ueg2.70061. PMID: 40569793; PMCID: PMC12529004.

Ácidos Biliares Fecais
1. CAMILLIERI, M. Advances in understanding of bile acid diarrhea. Expert Review of Gastroenterology & Hepatology, v. 8, n. 1, p. 49–61, 2014. DOI: 10.1586/17474124.2014.851598. PMID: 24151724.
2. HALILBASIC, E.; CLAUDEL, T.; TRAUNER, M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. Journal of Hepatology, v. 58, n. 1, p. 155–168, 2013. DOI: 10.1016/j.jhep.2012.08.002. PMID: 22885388.
3. VIJAYVARGIYA, P.; CAMILLERI, M.; RIEDEL, B.; BUSCAGLIA, C.; SINGH, R. Methods for diagnosis of bile acid malabsorption in clinical practice. Clinical Gastroenterology and Hepatology, v. 11, n. 10, p. 1232–1239, 2013. DOI: 10.1016/j.cgh.2013.03.032. PMID: 23591282.
4. MÜLLER-LISSNER, S. A.; PIRK, O. Irritable bowel syndrome in Germany: a cost of illness study. European Journal of Gastroenterology & Hepatology, v. 14, n. 12, p. 1325–1329, 2002. DOI: 10.1097/00042737-200212000-00010. PMID: 12468977.
5. FINDLAY, J. M.; EASTWOOD, M. A.; MITCHELL, W. D. The physical state of bile acids in the diarrhoeal stool of ileal dysfunction. Gut, v. 14, n. 4, p. 319–323, 1973. DOI: 10.1136/gut.14.4.319. PMID: 4706915; PMCID: PMC1412604.
6. McPHERSON-KAY, R. Fiber, stool bulk, and bile acid output: implications for colon cancer risk. Preventive Medicine, v. 16, n. 4, p. 540–544, 1987. DOI: 10.1016/0091-7435(87)90069-7. PMID: 2819848.

Gliadina sIgA Fecal
1. DIETERICH, W.; EHNIS, T.; BAUER, M.; DONNER, P.; VOLTA, U.; ROSELLI, M.; GELLER, F.; MANNINGER, K.; SCHUPPAN, D. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nature Medicine, v. 3, n. 7, p. 797–801, 1997. DOI: 10.1038/nm0797-797. PMID: 9212109.
2. RIEKEN, M.; WENZEL, B. E.; MOLL, R. Celiac disease: serologic diagnosis and follow-up with antibodies to gliadin and endomysium. Deutsche Medizinische Wochenschrift, v. 123, n. 51–52, p. 1454–1458, 1998. DOI: 10.1055/s-2007-1024128. PMID: 9852328.
3. GREEN, P. H. R.; JABRI, B.; et al. Diagnosis of celiac disease: current state and future perspectives. Clinical Perspectives in Gastroenterology, v. 1, n. 11, p. 133–138, 1998.
4. MOTHES, T. Diagnostik und Pathogenese der Zöliakie. Münchener Medizinische Wochenschrift, v. 139, n. 4, p. 111–116, 1997. PMID: 9053539.
5. KAPPLER, M.; KRAUSS-ETSCHMANN, S.; DIEHL, V.; ZEILHOFER, H.; KOLETZKO, S. Detection of secretory IgA antibodies against gliadin and human tissue transglutaminase in stool to screen for coeliac disease in children: validation study. BMJ (British Medical Journal), v. 332, n. 7535, p. 213–214, 2006. DOI: 10.1136/bmj.38688.654028.AE. PMID: 16377644; PMCID: PMC1352053.

IgA Secretora Fecal
1. BRANDTZAEG, P. Update on mucosal immunoglobulin A in gastrointestinal disease. Current Opinion in Gastroenterology, v. 26, n. 6, p. 554–563, 2010. DOI: 10.1097/MOG.0b013e32833dccf8. PMID: 20871234.
2. CORTHÉSY, B. Role of secretory IgA in infection and maintenance of homeostasis. Autoimmunity Reviews, v. 12, n. 6, p. 661–665, 2012. DOI: 10.1016/j.autrev.2012.02.014. PMID: 22398082.
3. KALACH, N.; CAILLAU, C.; DECALUWE, J.; BENHAMOU, P. H.; DUPONT, C. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnosis tools for digestive non-IgE-mediated cow’s milk allergy in toddlers. Clinical Chemistry and Laboratory Medicine (CCLM), v. 51, n. 2, p. 351–361, 2013. DOI: 10.1515/cclm-2012-0332. PMID: 23128860.
4. KAUR, R.; ADLOWITZ, D. G.; LEVY, O.; KAVANAGH, K. Antibody in middle ear fluid of children originates predominantly from sera and nasopharyngeal secretions. Clinical and Vaccine Immunology (CVI), v. 19, n. 10, p. 1593–1596, 2012. DOI: 10.1128/CVI.00359-12. PMID: 22815169.
5. KABEERDOSS, J.; SHANMUGASUNDARAM, R.; SRIDHAR, M.; RAMAKRISHNAN, A.; GONDI, C.; BALASUBRAMANIAN, P.; SRINIVASAN, V.; VENKATESAN, P.; SRINIVASAN, N. Effect of yoghurt containing Bifidobacterium lactis Bb12® on faecal excretion of secretory immunoglobulin A and human beta-defensin 2 in healthy adult volunteers. Nutrition Journal, v. 10, n. 1, p. 138, 2011. DOI: 10.1186/1475-2891-10-138. PMID: 22182278.
6. SENOL, A.; YAZAR, M.; BALCI, N.; SARIKAYA, H.; ERSOY, O. Effect of probiotics on aspirin-induced gastric mucosal lesions. Turkish Journal of Gastroenterology, v. 22, n. 1, p. 18–26, 2011. DOI: 10.4318/tjg.2011.0154. PMID: 21480173.
7. CHALKIAS, A.; DIMITRAKOPOULOU-SATRALOPOULOU, M.; KOURAKLIS, G.; MANOURAS, A. Patients with colorectal cancer are characterized by increased concentration of fecal Hb-Hp complex, myeloperoxidase, and secretory IgA. American Journal of Clinical Oncology, v. 34, n. 6, p. 561–566, 2011. DOI: 10.1097/COC.0b013e3181e84da5. PMID: 20505570.
8. MOHAN, R.; KOEBNIK, R.; FUREVIK, A.; et al. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatric Research, v. 64, n. 4, p. 418–422, 2008. DOI: 10.1203/PDR.0b013e318181b7e2. PMID: 18614959.
9. HOFMAN, L.; LE, T. Preliminary pediatric reference range for secretory IgA in saliva using an enzyme immunoassay. Clinical Chemistry, v. 48, supl. 6, p. A169–A170, 2002. PMID: 12045112.

CoproOne® Estroboloma

β-glucuronidase Fecal

1. MARUTI, S. S.; LI, L.; CHANG, J.-L.; PRUNTY, J.; SCHWARZ, Y.; LI, S. S.; KING, I. B.; POTTER, J. D.; LAMPE, J. W. Dietary and demographic correlates of serum β-glucuronidase activity. Nutrition and Cancer, v. 62, n. 2, p. 208–219, 2010. DOI: 10.1080/01635580903305375. PMID: 20155627.

2. O’LEARY, K. A.; DAY, A. J.; NEEDS, P. W.; SLY, W. S.; O’BRIEN, N. M.; WILLIAMSON, G. Flavonoid glucuronides are substrates for human liver β-glucuronidase. FEBS Letters, v. 503, n. 1, p. 103–106, 2001. DOI: 10.1016/S0014-5793(01)02717-6. PMID: 11513863.

3. DE GRAAF, M.; BOVEN, E.; SCHEEREN, H. W.; HAISMA, H. J.; PINEDO, H. M. Beta-glucuronidase-mediated drug release. Current Pharmaceutical Design, v. 8, n. 15, p. 1391–1403, 2002. DOI: 10.2174/1381612023394084. PMID: 12052224.

4. KWA, M.; PLOTTEL, C. S.; BLASER, M. J.; ADAMS, S. The intestinal microbiome and estrogen receptor–positive female breast cancer. Journal of the National Cancer Institute, v. 108, n. 8, 2016. DOI: 10.1093/jnci/djw029. PMID: 26908441.

5. MROCZYNSKA, M.; LIBUDZISZ, Z. β-Glucuronidase and β-glucosidase activity of Lactobacillus and Enterococcus isolated from human feces. Polish Journal of Microbiology, v. 59, n. 4, p. 265–269, 2010. PMID: 21466091.

6. WALLACE, B. D.; ROBERTS, A. B.; et al. Structure and inhibition of microbiome β-glucuronidase essential to the alleviation of cancer drug toxicity. Chemistry & Biology, v. 22, n. 9, p. 1238–1249, 2015. DOI: 10.1016/j.chembiol.2015.07.003. PMID: 26343552.

7. LASKY-SU, J.; DAHLIN, A.; et al. Metabolome alterations in severe critical illness and vitamin D status. Critical Care, v. 21, n. 1, p. 193, 2017. DOI: 10.1186/s13054-017-1794-y. PMID: 28764722.

8. HU, S.; DING, Q.; ZHANG, W.; KANG, M.; MA, J.; ZHAO, L. Gut microbial β-glucuronidase: a vital regulator in female estrogen metabolism. Gut Microbes, v. 15, n. 1, p. 2236749, 2023. DOI: 10.1080/19490976.2023.2236749. PMID: 37559394; PMCID: PMC10416750.

9. SPERKER, B.; BACKMAN, J. T.; KROEMER, H. K. The role of β-glucuronidase in drug disposition and drug targeting in humans. Clinical Pharmacokinetics, v. 33, n. 1, p. 18–31, 1997. DOI: 10.2165/00003088-199733010-00003. PMID: 9250421.

10. WALLACE, B. D.; WANG, H.; LANE, K. T.; SCOTT, J. E.; ORANS, J.; KOO, J. S.; VENKATESH, M.; JOBIN, C.; YEH, L. A.; MANI, S.; REDINBO, M. R. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science, v. 330, n. 6005, p. 831–835, 2010. DOI: 10.1126/science.1191175. PMID: 21051639; PMCID: PMC3110694.

11. ERVIN, S. M.; LI, H.; LIM, L.; ROBERTS, L. R.; LIANG, X.; MANI, S.; REDINBO, M. R. Gut microbial β-glucuronidases reactivate estrogens as components of the estrobolome that reactivate estrogens. Journal of Biological Chemistry, v. 294, n. 49, p. 18586–18599, 2019. DOI: 10.1074/jbc.RA119.010950. PMID: 31636122; PMCID: PMC6901331.

CoproOne® EDN

EDN Fecal

1. KONIKOFF, M. R.; NOEL, R. J.; BLANCHARD, C.; PUTNAM, P. E.; COLLINS, M. H.; ASSA’AD, A. H.; ROTHENBERG, M. E. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clinical Gastroenterology and Hepatology, v. 4, n. 11, p. 1328–1336, 2006. DOI: 10.1016/j.cgh.2006.07.010. PMID: 17059896.

2. LOTFI, R.; LOTZE, M. T. Eosinophils induce dendritic cell maturation, regulating immunity. Journal of Leukocyte Biology, v. 83, n. 3, p. 456–460, 2008. DOI: 10.1189/jlb.0807581. PMID: 18077718.

3. BENTZ, S.; HAAG, S.; WIEDBRAUCK, H.; SCHOEPFER, A.; BRONNER, M.; MULLER, S.; PFEFFERKORN, M.; BECKMANN, K.; GREINWALD, R.; GOEBELL, H. Clinical relevance of IgG antibodies against food antigens in Crohn’s disease: a double-blind cross-over diet intervention study. Digestion, v. 81, n. 4, p. 252–264, 2010. DOI: 10.1159/000264649. PMID: 20051638.

4. KALACH, N.; CAILLAU, C.; DECALUWE, J.; BENHAMOU, P. H.; DUPONT, C. Intestinal permeability and fecal eosinophil-derived neurotoxin are the best diagnostic tools for digestive non-IgE-mediated cow’s milk allergy in toddlers. Clinical Chemistry and Laboratory Medicine (CCLM), v. 51, n. 2, p. 351–361, 2013. DOI: 10.1515/cclm-2012-0332. PMID: 23128860.

5. WADA, T.; TOMA, T.; MURAOKA, M.; MATSUDA, Y.; YACHIE, A. Elevation of fecal eosinophil-derived neurotoxin in infants with food protein-induced enterocolitis syndrome. Pediatric Allergy and Immunology, v. 25, n. 6, p. 617–619, 2014. DOI: 10.1111/pai.12254. PMID: 24890227.

6. LING LUNDSTRÖM, M.; PETERSON, C.; HEDIN, C. R. H.; BERGEMALM, D.; LAMPINEN, M.; MAGNUSSON, M. K.; KEITA, Å. V.; KRUSE, R.; LINDQVIST, C. M.; REPSILBER, D.; D’AMATO, M.; HJORTSWANG, H.; STRID, H.; SÖDERHOLM, J. D.; ÖHMAN, L.; VENGE, P.; HALFVARSON, J.; CARLSON, M.; BIOIBD CONSORTIUM. Faecal biomarkers for diagnosis and prediction of disease course in treatment-naïve patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, v. 60, n. 6, p. 765–777, 2024. DOI: 10.1111/apt.18154. PMID: 38997818.

7. ROCA, M.; RODRIGUEZ VARELA, A.; DONAT, E.; CANO, F.; HERVAS, D.; ARMISEN, A.; VAYA, M. J.; SJÖLANDER, A.; RIBES-KONINCKX, C. Fecal calprotectin and eosinophil-derived neurotoxin in healthy children between 0 and 12 years. Journal of Pediatric Gastroenterology and Nutrition, v. 65, n. 4, p. 394–398, 2017. DOI: 10.1097/MPG.0000000000001542. PMID: 28169973.

8. SAITOH, O.; KOJIMA, K.; SUGI, K.; MATSUSE, R.; UCHIDA, K.; TABATA, K.; NAKAGAWA, K.; KAYAZAWA, M.; HIRATA, I.; KATSU, K. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. American Journal of Gastroenterology, v. 94, n. 12, p. 3513–3520, 1999. DOI: 10.1111/j.1572-0241.1999.01640.x. PMID: 10606313.

CoproOne® SII

Serotonina Fecal

1. GERSHON, M. D. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Current Opinion in Endocrinology, Diabetes and Obesity, v. 20, n. 1, p. 14–21, 2013. DOI: 10.1097/MED.0b013e32835bc703. PMID: 23222853.

2. FARZAEI, M. H.; BAHRAMSOLTANI, R.; ABDOLLAHI, M.; RAHIMI, R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. Journal of Neurogastroenterology and Motility, v. 22, n. 4, p. 558–574, 2016. DOI: 10.5056/jnm16001. PMID: 27426254.

3. COATES, M. D.; MAWE, G. M.; SHAW, R. D.; CHIARO, T. R.; GERRITSEN, M. E.; CRAWFORD, D. A.; COOK, E. H. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology, v. 126, n. 7, p. 1657–1664, 2004. DOI: 10.1053/j.gastro.2004.02.009. PMID: 15188158.

4. YAZAR, A.; BUYUKAFPAR, K.; POLAT, G.; et al. The urinary 5-hydroxyindole acetic acid and plasma nitric oxide levels in irritable bowel syndrome: a preliminary study. Scottish Medical Journal, v. 50, n. 1, p. 27–29, 2005. DOI: 10.1177/003693300505000108. PMID: 15801591.

5. DUNLOP, S. P.; COLEMAN, N. S.; BLACKSHAW, E.; PERKINS, A. C.; TRAUB, R. J.; WINGATE, D. L.; SPILLER, R. C. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clinical Gastroenterology and Hepatology, v. 3, n. 4, p. 349–357, 2005. DOI: 10.1016/S1542-3565(04)00726-8. PMID: 15822038.

6. JIN, D. C.; KIM, D. Y.; KIM, J. H.; KIM, T. H.; PARK, S. J.; KIM, J. W.; HONG, S. N. Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome. World Journal of Gastroenterology, v. 22, n. 36, p. 8137–8148, 2016. DOI: 10.3748/wjg.v22.i36.8137. PMID: 27784955.

7. YU, F. Y.; HUANG, S. G.; ZHANG, H. Y.; YE, H.; CHI, H. G.; ZOU, Y.; et al. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis. World Journal of Gastroenterology, v. 22, n. 14, p. 3451–3459, 2016. DOI: 10.3748/wjg.v22.i14.3451. PMID: 27076786.

8. FU, R.; CHEN, M.; CHEN, Y.; MAO, G.; LIU, S. Expression and clinical significance of 5-HT and 5-HT3R in the intestinal mucosa of patients with diarrhea-type irritable bowel syndrome. Experimental and Therapeutic Medicine, v. 13, n. 6, p. 3077–3082, 2019. DOI: 10.3892/etm.2019.7297. PMID: 31037238.

9. CREMON, C.; CARINI, G.; WANG, B.; VASINA, V.; COGLIANDRO, R. F.; DE GIORGIO, R.; STANGHELLINI, V.; GRUNDY, D.; TONINI, M.; DE PONTI, F.; BARBARA, G. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. American Journal of Gastroenterology, v. 106, n. 7, p. 1290–1298, 2011. DOI: 10.1038/ajg.2011.86. PMID: 21448149.

10. LUO, M.; ZHUANG, X.; TIAN, Z.; XIONG, L. Alterations in short-chain fatty acids and serotonin in irritable bowel syndrome: a systematic review and meta-analysis. BMC Gastroenterology, v. 21, n. 1, p. 14, 2021. DOI: 10.1186/s12876-020-01577-5. PMID: 33407453.

GABA Fecal

1. DE LEON, A. S.; TADI, P. Biochemistry, Gamma Aminobutyric Acid. StatPearls Publishing, 2022. Atualizado em 9 mai. 2021. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK551683/.

2. LI, K.; XU, E. The role and the mechanism of gamma-aminobutyric acid during central nervous system development. Neuroscience Bulletin, v. 24, p. 195–200, 2008. DOI: 10.1007/s12264-008-0118-4. PMID: 18446487.

3. TORRES-GONZÁLEZ, M. I.; MANZANO-MORENO, F. J.; VALLECILLO-CAPILLA, M. F.; OLMEDO-GAYA, M. V. Preoperative oral pregabalin for anxiety control: a systematic review. Clinical Oral Investigations, v. 24, n. 7, p. 2219–2228, 2020. DOI: 10.1007/s00784-019-03124-z. PMID: 31773342.

4. AGGARWAL, S.; AHUJA, V.; PAUL, J. Dysregulation of GABAergic signalling contributes in the pathogenesis of diarrhea predominant irritable bowel syndrome. Journal of Neurogastroenterology and Motility, v. 24, n. 3, p. 422–430, 2018. DOI: 10.5056/jnm17100. PMID: 29713288.

5. STRANDWITZ, P.; KIM, K. H.; TEREKHOVA, D.; LIU, J. K.; SHARMA, A.; LEVERING, J.; McDONALD, D.; DIETRICH, D.; RAMADHAR, T. R.; LEKBUA, A.; MROUE, N.; LISTON, C.; STEWART, E. J.; DUBIN, M. J.; ZENGLER, K.; KNIGHT, R.; GILBERT, J. A.; CLARDY, J.; LEWIS, K. GABA-modulating bacteria of the human gut microbiota. Nature Microbiology, v. 4, n. 3, p. 396–403, 2019. DOI: 10.1038/s41564-018-0307-3. PMID: 30664615.

6. YUNES, R. A.; POLUEKTOVA, E. U.; DYACHKOVA, M. S.; KLIMINA, K. M.; KOVTUN, A. S.; AVERINA, O. V.; ORLOVA, V. S.; DANILENKO, V. N. GABA production and structure of gadB/gadC genes in Lactobacillus and Bifidobacterium strains from human microbiota. Anaerobe, v. 42, p. 197–204, 2016. DOI: 10.1016/j.anaerobe.2016.10.011. PMID: 27773422.

7. ALTAIB, H.; NAKAMURA, K.; ABE, M.; BADR, Y.; YANASE, E.; NOMURA, I.; SUZUKI, T. Differences in the concentration of the fecal neurotransmitters GABA and glutamate are associated with microbial composition among healthy human subjects. Microorganisms, v. 9, n. 2, p. 378, 2021. DOI: 10.3390/microorganisms9020378. PMID: 33668574.

8. STRANDWITZ, P. Neurotransmitter modulation by the gut microbiota. Brain Research, v. 1693, p. 128–133, 2018. DOI: 10.1016/j.brainres.2018.03.015. PMID: 29572013.

9. BAJ, A.; MORO, E.; BISTOLETTI, M.; ORLANDI, V.; CREMA, F.; GIARONI, C. Glutamatergic signaling along the microbiota-gut-brain axis. International Journal of Molecular Sciences, v. 20, n. 6, p. 1482, 2019. DOI: 10.3390/ijms20061482. PMID: 30875702.

10. RASKOV, H.; BURCHARTH, J.; POMMERGAARD, H. C.; ROSENBERG, J. Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes, v. 7, n. 5, p. 365–383, 2016. DOI: 10.1080/19490976.2016.1218585. PMID: 27579552.

11. PAPALINI, S.; MICHELS, F.; KOHN, N.; WEGMAN, J.; VAN HEMERT, S.; ROELOFS, K.; et al. Stress matters: randomized controlled trial on the effect of probiotics on neurocognition. Neurobiology of Stress, v. 10, p. 100141, 2019. DOI: 10.1016/j.ynstr.2019.100141. PMID: 31289555.

12. BAGGA, D.; REICHERT, J. L.; KOSCHUTNIG, K.; AIGNER, C. S.; HOLZER, P.; KOSKINEN, K.; et al. Probiotics drive gut microbiome triggering emotional brain signatures. Gut Microbes, v. 9, n. 6, p. 486–496, 2018. DOI: 10.1080/19490976.2018.1460015. PMID: 29634387.

13. PINTO-SANCHEZ, M. I.; HALL, G. B.; GHAJAR, K.; NARDELLI, A.; BOLINO, C.; LAU, J. T.; et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology, v. 153, n. 2, p. 448–459.e8, 2017. DOI: 10.1053/j.gastro.2017.05.003. PMID: 28483500.

Triptofano Fecal

1. GRIFKA-WALK, H. M.; JENKINS, B. R.; KOMINSKY, D. J. Amino acid tryptophan: the far-out impacts of host and commensal tryptophan metabolism. Frontiers in Immunology, v. 12, p. 1–10, 2021. DOI: 10.3389/fimmu.2021.653208. PMID: 33868178.

2. LI, M.; LIU, S.; WANG, M.; HU, J.; LIU, C.; HUANG, Y. Gut microbiota dysbiosis associated with bile acid metabolism in neonatal cholestasis. Disease Science Reports, v. 20, p. 7686, 2020. DOI: 10.1038/s41598-020-64604-5. PMID: 32499327.

3. COATES, M. D.; MAWE, G. M.; SHAW, R. D.; et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology, v. 126, p. 1657–1664, 2004. DOI: 10.1053/j.gastro.2004.02.009. PMID: 15188158.

4. YAZAR, A.; BUYUKAFPAR, K.; POLAT, G.; et al. The urinary 5-hydroxyindole acetic acid and plasma nitric oxide levels in irritable bowel syndrome: a preliminary study. Scottish Medical Journal, v. 50, p. 27–29, 2005. DOI: 10.1177/003693300505000108. PMID: 15801591.

5. DUNLOP, S. P.; COLEMAN, N. S.; BLACKSHAW, E.; et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clinical Gastroenterology and Hepatology, v. 3, n. 4, p. 349–357, 2005. DOI: 10.1016/S1542-3565(04)00726-8. PMID: 15822038.

6. KENNEDY, P. J.; CRYAN, J. F.; DINAN, T. G.; CLARKE, G. Kynurenine pathway metabolism and the microbiota–gut–brain axis. Neuropharmacology, v. 112, p. 399–412, 2017. DOI: 10.1016/j.neuropharm.2016.07.002. PMID: 27392471.

7. WANG, J.; SIMONAVICUS, N.; WU, X.; SWAMINATH, G.; REAGAN, J.; TIAN, H.; LING, L. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. Journal of Biological Chemistry, v. 281, p. 22021–22028, 2006. DOI: 10.1074/jbc.M603503200. PMID: 16754668.

8. KESTETHLYI, D.; TROOST, F. J.; JONKERS, D. M.; KRUIMEL, J. W.; LEUE, C.; MASCLEE, A. A. M. Decreased levels of kynurenic acid in the intestinal mucosa of IBS patients: relation to serotonin and psychological state. Journal of Psychosomatic Research, v. 73, p. 401–504, 2013. DOI: 10.1016/j.jpsychores.2012.09.003. PMID: 24070573.

9. ZHAO, Z. H.; FAN, X.; XUE, Y. H.; ZU, H.; HAN, Y.; MA, F.; ZHOU, D.; LIU, X. L.; CUI, A.; LIU, Z. J.; LIU, Y.; GAO, J.; PAN, Q.; LI, Y.; FAN, G. Indole-3-propionic acid inhibits gut dysbiosis and endotoxemia to attenuate spontaneous steatohepatitis in rats. Experimental and Molecular Medicine, v. 51, n. 9, p. 1–14, 2019. DOI: 10.1038/s12276-019-0304-5. PMID: 31537855.

10. SHEN, Y.; SHEN, Q.; ZHEN, M.; ZHANG, Z.; XIAO, S. L.; CUI, W.; WAN, Y.; LIANG, S.; SHANG, E.; QIAN, D.; LU, L.; LIZHONG, D. Deoxycholic acid ameliorates ulcerative colitis in mice via regulating gut microbiota and its metabolites. Applied Microbiology and Biotechnology, v. 104, n. 13, p. 5999–6012, 2020. DOI: 10.1007/s00253-020-10665-1. PMID: 32445038.

11. WANG, H.; ZADEH, K.; VEKARIYA, R. G.; YE, Y.; MOHAMADZADEH, M. Tryptophan metabolism and gut-brain homeostasis. International Journal of Molecular Sciences, v. 22, n. 6, p. 2973, 2021. DOI: 10.3390/ijms22062973. PMID: 33803715.

12. SCOTT, S. A.; FU, J.; CHANG, P. V. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America (PNAS), v. 117, n. 32, p. 19376–19387, 2020. DOI: 10.1073/pnas.2000047117. PMID: 32719123.

13. VAN THIEL, I. A. M.; BOTSCHUIJVER, S.; DE JONGE, W. J.; SEPPEN, J. J. Painful interactions: microbial compounds and visceral pain. Biochimica et Biophysica Acta (Molecular Basis of Disease), v. 1866, n. 10, p. 165534, 2020. DOI: 10.1016/j.bbadis.2020.165534. PMID: 32712340.

14. LIANG, H. Dietary L-tryptophan supplementation enhances the intestinal mucosal barrier function in weaned piglets: implication of tryptophan-metabolizing microbiota. International Journal of Molecular Sciences, v. 20, n. 20, p. 20–20, 2019. DOI: 10.3390/ijms20205070. PMID: 31614652.

15. PETERSON, L. W.; ARTIS, D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nature Reviews Immunology, v. 14, p. 141–153, 2014. DOI: 10.1038/nri3608. PMID: 24566914.

16. MESSORI, S.; TREVISI, P.; SIMONGIOVANNI, A.; PRIORI, D.; BOSI, P. Effect of susceptibility to enterotoxigenic Escherichia coli F4 and of dietary tryptophan on gut microbiota diversity observed in healthy young pigs. Veterinary Microbiology, v. 162, p. 173–179, 2013. DOI: 10.1016/j.vetmic.2012.10.015. PMID: 23159308.

Histamina Fecal

1. BARCIK, W.; WAWRZYNIAK, M.; AKDIS, C. A.; O’MAHONY, L. Immune regulation by histamine and histamine-secreting bacteria. Current Opinion in Immunology, v. 48, p. 108–113, 2017. DOI: 10.1016/j.coi.2017.08.014.

2. SMOLINSKA, S.; JUTEL, M.; CRAMERI, R.; O’MAHONY, L. Histamine and gut mucosal immune regulation. Allergy, v. 69, n. 3, p. 273–281, 2014. DOI: 10.1111/all.12330.

3. KOVACOVA-HANUSKOVA, E.; BUDAY, T.; GAVLIAKOVA, S.; PLEVKOVA, J. Histamine, histamine intoxication and intolerance. Allergologia et Immunopathologia (Madrid), v. 43, n. 5, p. 498–506, 2015. DOI: 10.1016/j.aller.2015.05.001.

4. NEUHUBER, W.; WÖRL, J. Monoamines in the enteric nervous system. Histochemistry and Cell Biology, v. 150, n. 6, p. 703–709, 2018. DOI: 10.1007/s00418-018-1723-4.

5. TOKITA, Y.; AKIHO, H.; NAKAMURA, K.; IHARA, E.; YAMAMOTO, M. Contraction of gut smooth muscle cells assessed by fluorescence imaging. Journal of Pharmacological Sciences, v. 127, n. 3, p. 344–351, 2015. DOI: 10.1016/j.jphs.2015.01.006.

6. POTTS, R. A.; TIFFANY, C. M.; PAKPOUR, N.; LOKKEN, K. L.; TIFFANY, C. R.; CHEUNG, K.; TSOLIS, R. M.; LUCKHART, S. Mast cells and histamine alter intestinal permeability during malaria parasite infection. Immunobiology, v. 221, n. 3, p. 468–474, 2016. DOI: 10.1016/j.imbio.2015.11.007.

7. FABISIAK, A.; WŁODARCZYK, J.; FABISIAK, N.; STORR, M.; FICHNA, J. Targeting histamine receptors in irritable bowel syndrome: a critical appraisal. Journal of Neurogastroenterology and Motility, v. 23, n. 3, p. 341–348, 2017. DOI: 10.5056/jnm16090.

8. NAM, Y.; MIN, Y. S.; SOHN, U. D. Recent advances in pharmacological research on the management of irritable bowel syndrome. Archives of Pharmacal Research, v. 41, n. 9, p. 955–966, 2018. DOI: 10.1007/s12272-018-1059-7.

9. BARBARA, G.; WANG, B.; STANGHELLINI, V.; DE GIORGIO, R.; CREMON, C.; DI NARDO, G.; TREVISANI, M.; CAMPI, B.; GEPPETTI, P.; TONINI, M.; et al. Mast cell-dependent excitation of visceral nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology, v. 132, n. 1, p. 26–37, 2007. DOI: 10.1053/j.gastro.2006.10.030.

10. GALLARDO, P.; IZQUIERDO, M.; VIDAL, R. M.; SOTO, F.; OSSA, J. C.; FARFAN, M. J. Gut microbiota–metabolome changes in children with diarrhea by diarrheagenic E. coli. Frontiers in Cellular and Infection Microbiology, v. 10, n. 485, p. 1–10, 2020. DOI: 10.3389/fcimb.2020.00485.

11. MCINTOSH, K.; REED, D. E.; SCHNEIDER, T.; DANG, F.; KESHTELI, A. H.; DE PALMA, G.; MADSEN, K.; BERCIK, P.; VANNER, S. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut, v. 66, n. 7, p. 1241–1251, 2017. DOI: 10.1136/gutjnl-2015-311339.

12. NEREE, A. T.; SORET, R.; MARCOCCI, L.; PIETRANGELI, P.; PILON, N.; MATEESCU, M. A. Vegetal diamine oxidase alleviates histamine-induced contraction of colonic muscles. Scientific Reports, v. 10, n. 21563, p. 1–9, 2020. DOI: 10.1038/s41598-020-78134-3.

13. CAMILLERI, M.; BOECKXSTAENS, G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut, v. 66, n. 5, p. 966–974, 2017. DOI: 10.1136/gutjnl-2016-313425.

14. BARCIK, W.; PUGIN, B.; BRESCÓ, M. S.; WESTERMANN, P.; RINALDI, A.; GROEGER, D.; VAN ELST, D.; SOKOLOWSKA, M.; KRAWCZYK, K.; FREI, R.; et al. Bacterial secretion of histamine within the gut influences immune responses within the lung. Allergy, v. 74, n. 5, p. 899–909, 2019. DOI: 10.1111/all.13660.

15. SCHINK, M.; KONTUREK, P. C.; TIETZ, E.; et al. Microbial patterns in patients with histamine intolerance. Journal of Physiology and Pharmacology, v. 69, n. 4, p. 579–593, 2018. DOI: 10.26402/jpp.2018.4.09.

16. CHOI, I. Y.; KIM, J.; KIM, S. H.; BAN, O. H.; YANG, J.; PARK, M. K. Safety evaluation of Bifidobacterium breve IDCC4401 isolated from infant feces for use as a commercial probiotic. Journal of Microbiology and Biotechnology, v. 31, n. 7, p. 949–955, 2021. DOI: 10.4014/jmb.2103.03041.

17. SHARIKADZE, O.; ZUBCHENKO, S.; MARUNIAK, S.; YURIEV, S. Investigation of protective effects of synbiotics on allergopathy formation. Georgian Medical News, n. 280–281, p. 90–94, 2018. PMID: 30173449.

18. PITHVA, S.; SHEKH, S.; DAVE, J.; VYAS, B. R. M. Probiotic attributes of autochthonous Lactobacillus rhamnosus strains of human origin. Applied Biochemistry and Biotechnology, v. 173, n. 1, p. 259–277, 2014. DOI: 10.1007/s12010-014-0839-9.

DBS® Intolerância Histamínica

Histamina no Sangue

1. CHEN, Q.; SHAO, L.; LI, Y.; DAI, M.; LIU, H.; XIANG, N.; CHEN, H. Tanshinone IIA alleviates ovalbumin-induced allergic rhinitis symptoms by inhibiting Th2 cytokine production and mast cell histamine release in mice. Pharmaceutical Biology, v. 60, n. 1, p. 326–333, 2022. DOI: 10.1080/13880209.2022.2034894. PMID: 35167426; PMCID: PMC8856108.

2. COULSON, J.; THOMPSON, J. P. Paracetamol (acetaminophen) attenuates in vitro mast cell and peripheral blood mononucleocyte histamine release induced by N-acetylcysteine. Clinical Toxicology (Philadelphia), v. 48, n. 2, p. 111–114, 2010. DOI: 10.3109/15563650903520959. PMID: 20136478.

3. DEMOLY, P.; LEBEL, B.; MESSAAD, D.; SAHLA, H.; RONGIER, M.; DAURÈS, J. P.; GODARD, P.; BOUSQUET, J. Predictive capacity of histamine release for the diagnosis of drug allergy. Allergy, v. 54, n. 5, p. 500–506, 1999. DOI: 10.1034/j.1398-9995.1999.00020.x. PMID: 10380783.

4. KOVACOVA-HANUSKOVA, E.; BUDAY, T.; GAVLIAKOVA, S.; PLEVKOVA, J. Histamine, histamine intoxication and intolerance. Allergologia et Immunopathologia (Madrid), v. 43, n. 5, p. 498–506, 2015. DOI: 10.1016/j.aller.2015.05.001. PMID: 26163023.

5. MATSUMOTO, J.; MATSUDA, H. Mast-cell-dependent histamine release after praziquantel treatment of Schistosoma japonicum infection: implications for chemotherapy-related adverse effects. Parasitology Research, v. 88, n. 10, p. 888–893, 2002. DOI: 10.1007/s00436-002-0677-5. PMID: 12209328.

6. SERRIER, J.; KHOY, K.; PETIT, G.; PARIENTI, J. J.; LAROCHE, D.; MARIOTTE, D.; LE MAUFF, B. Mediators of anaphylactic reactions: tryptase and histamine stability in whole blood. Allergy, v. 76, n. 5, p. 1579–1583, 2021. DOI: 10.1111/all.14663. PMID: 33202058.

Diamina Oxidase (DAO)

1. SATTLER, J.; LORZ, W.; KÖNIG, K.; LÖTSCH, J.; MÄRKI, F.; SENGER, C.; ZELLNER, R. Food-induced histaminosis as an epidemiological problem: plasma histamine elevation and haemodynamic alterations after oral histamine administration and blockade of diamine oxidase (DAO). Agents and Actions, v. 23, p. 361–365, 1988. DOI: 10.1007/BF01966441. PMID: 2903903.

2. TUFVESSON, G.; BERG, G.; WOLD, L. E. Determination of diamine oxidase activity in normal human blood serum. Scandinavian Journal of Clinical and Laboratory Investigation, v. 24, p. 163–168, 1969. DOI: 10.3109/00365516909080183. PMID: 5793948.

3. WANTKE, F.; GÖTZ, M.; GROSSMANN, A.; JARISCH, R. The red wine maximization test: drinking histamine-rich wine induces a transient increase of plasma diamine oxidase activity in healthy volunteers. Inflammation Research, v. 48, n. 4, p. 169–170, 1999. DOI: 10.1007/s000110050430. PMID: 10219686.

4. WANTKE, F.; GOTZ, M.; JARISCH, R. The red wine provocation test: intolerance to histamine as a model for food intolerance. Allergy Proceedings, v. 15, n. 1, p. 27–32, 1994. DOI: 10.2500/108854194778816869. PMID: 8162357.

5. WANTKE, F.; GOTZ, M.; JARISCH, R. Daily variations of serum diamine oxidase and the influence of H1 and H2 blockers: a critical approach to routine diamine oxidase assessment. Inflammation Research, v. 47, n. 9, p. 396–400, 1998. DOI: 10.1007/s000110050370. PMID: 9778653.

6. JARISCH, R.; RAITH, M.; WÜTHRICH, B. Role of food allergy and food intolerance in recurrent urticaria. In: WÜTHRICH, B. (ed.). The Atopy Syndrome in the Third Millennium. Current Problems in Dermatology. Basel: Karger, v. 28, p. 64–73, 1999. DOI: 10.1159/000060667. PMID: 10393456.

7. WANTKE, F.; GÖTZ, M.; JARISCH, R. Histamine-free diet: treatment of choice for histamine-induced food intolerance and supporting treatment for chronic headaches. Clinical and Experimental Allergy, v. 23, n. 12, p. 982–985, 1993. DOI: 10.1111/j.1365-2222.1993.tb00287.x. PMID: 8312701.

8. GÖTZ, M.; JARISCH, R.; HEMMER, W.; WÜTHRICH, B. Histamin-Intoleranz und Diaminooxidasemangel. Allergologie, v. 9, p. 426–430, 1996.

JARISCH, R. Histamin-Intoleranz. 1. Auflage. Stuttgart: Thieme-Verlag, 1999. ISBN: 9783131081713.

DBS® Neuroinflamação

Triptofano no Sangue

1. BRANDACHER, G.; HOELLER, E.; FUCHS, D.; WEISS, H. G. Chronic immune activation underlies morbid obesity: is IDO a key player? Current Drug Metabolism, v. 8, n. 3, p. 289–295, 2007. PMID: 17430101.

2. CHUANG, S. C.; FANIDI, A.; UELAND, P. M. et al. Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention, v. 23, n. 3, p. 461–468, 2014. DOI: 10.1158/1055-9965.EPI-13-0664. PMID: 24399638.

3. CIORBA, M. A. Indoleamine 2,3-dioxygenase in intestinal disease. Current Opinion in Gastroenterology, v. 29, n. 2, p. 146–152, 2013. DOI: 10.1097/MOG.0b013e32835ced86. PMID: 23325085.

4. CREELAN, B. C.; ANTONIA, S.; BEPLER, G.; GARRETT, T. J.; SIMON, G. R.; SOLIMAN, H. H. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small-cell lung cancer. OncoImmunology, v. 2, n. 3, e23428, 2013. DOI: 10.4161/onci.23428. PMID: 23894763.

5. DOLINA, S.; MARGALIT, D.; MALITSKY, S.; RABINKOV, A. Attention-deficit hyperactivity disorder (ADHD) as a pyridoxine-dependent condition: urinary diagnostic biomarkers. Medical Hypotheses, v. 82, n. 1, p. 111–116, 2014. DOI: 10.1016/j.mehy.2013.10.018. PMID: 24210978.

6. GROZDICS, E.; BERTA, L.; BAJNOK, A.; VERES, G.; ILISZ, I.; KLIVÉNYI, P.; RIGÓ, J. Jr.; TOLDI, G. B7 costimulation and intracellular indoleamine-2,3-dioxygenase (IDO) expression in peripheral blood of healthy pregnant and non-pregnant women. BMC Pregnancy and Childbirth, v. 14, n. 306, p. 1–8, 2014. DOI: 10.1186/1471-2393-14-306. PMID: 25192867.

7. GUPTA, N. K.; THAKER, A. I.; KANURI, N.; RIEHL, T. E.; ROWLEY, C. W.; STENSON, W. F.; CIORBA, M. A. Serum analysis of tryptophan catabolism pathway: correlation with Crohn’s disease activity. Inflammatory Bowel Diseases, v. 18, n. 7, p. 1214–1220, 2012. DOI: 10.1002/ibd.21854. PMID: 21830277.

8. KIM, H.; CHEN, L.; LIM, G.; SUNG, B.; WANG, S.; McCABE, M. F.; YANG, L.; TIAN, Y.; MAO, J. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. Journal of Clinical Investigation, v. 122, n. 8, p. 2940–2954, 2012. DOI: 10.1172/JCI61884. PMID: 22863624.

9. MIURA, H.; OZAKI, N.; SAWADA, M.; ISOBE, K.; OHTA, T.; NAGATSU, T. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism. Stress, v. 11, n. 3, p. 198–209, 2008. DOI: 10.1080/10253890701553968. PMID: 18465488.

10. MYINT, A. M.; BONDY, B.; BAGHAI, T. C.; ESER, D.; NOTHDURFTER, C.; SCHÜLE, C.; ZILL, P.; MÜLLER, N.; RUPPRECHT, R.; SCHWARZ, M. J. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-γ gene. Brain, Behavior, and Immunity, v. 31, p. 128–133, 2013. DOI: 10.1016/j.bbi.2013.03.003. PMID: 23523778.

11. PEDERSEN, E. R.; SVINGEN, G. F.; SCHARTUM-HANSEN, H.; et al. Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. European Heart Journal, v. 34, n. 34, p. 2689–2696, 2013. DOI: 10.1093/eurheartj/eht286. PMID: 23897649.

12. RISTAGNO, G.; LATINI, R.; VAAHERSALO, J.; et al. Early activation of the kynurenine pathway predicts early death and long-term outcome in patients resuscitated from out-of-hospital cardiac arrest. Journal of the American Heart Association, v. 3, e001094, 2014. DOI: 10.1161/JAHA.114.001094. PMID: 25037015.

13. SULO, G.; VOLLSET, S. E.; NYGÅRD, O.; et al. Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults: the Hordaland Health Study. International Journal of Cardiology, v. 168, n. 2, p. 1435–1440, 2013. DOI: 10.1016/j.ijcard.2012.12.055. PMID: 23357186.

14. SUZUKI, Y.; SUDA, T.; ASADA, K.; et al. Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis. Clinical and Vaccine Immunology, v. 19, n. 3, p. 436–442, 2012. DOI: 10.1128/CVI.05694-11. PMID: 22259280.

15. WILSON, S. T.; STANLEY, B.; BRENT, D. A.; OQUENDO, M. A.; HUANG, Y. Y.; MANN, J. J. The tryptophan hydrolase-1 A218C polymorphism is associated with diagnosis, but not suicidal behavior, in borderline personality disorder. American Journal of Medical Genetics B (Neuropsychiatric Genetics), v. 150B, n. 2, p. 202–208, 2009. DOI: 10.1002/ajmg.b.30793. PMID: 18671985.

16. YAN, E. B.; FRUGIER, T.; LIM, C. K.; et al. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans. Journal of Neuroinflammation, v. 12, n. 1, p. 110, 2015. DOI: 10.1186/s12974-015-0327-z. PMID: 26077710.

17. ZUO, H.; UELAND, P. M.; ULVIK, A.; et al. Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality. American Journal of Epidemiology, v. 183, n. 4, p. 249–258, 2016. DOI: 10.1093/aje/kwv242. PMID: 26823436.

18. HILDEBRAND, P.; KÖNIGSCHULTE, W.; GABER, T. J.; BUBENZER-BUSCH, S.; HELMBOLD, K.; BISKUP, C. S.; Langen, K. J.; Fink, G. R.; ZEPF, F. D. Effects of dietary tryptophan and phenylalanine-tyrosine depletion on phasic alertness in healthy adults: a pilot study. Food & Nutrition Research, v. 59, p. 26407, 2015. DOI: 10.3402/fnr.v59.26407. PMID: 25999861.

19. ZIMMER, P.; SCHMIDT, M. E.; PRENTZELL, M. T.; et al. Resistance exercise reduces kynurenine pathway metabolites in breast cancer patients undergoing radiotherapy. Frontiers in Oncology, v. 9, p. 962, 2019. DOI: 10.3389/fonc.2019.00962. PMID: 31681625.

Quinurenina no Sangue

1. BIPATH, P.; LEVAY, P. F.; VILJOEN, M. The kynurenine pathway activities in a sub-Saharan HIV/AIDS population. BMC Infectious Diseases, v. 15, n. 1, p. 346, 2015. DOI: 10.1186/s12879-015-1087-5. PMID: 26286521.

2. CAVIA-SAIZ, M.; MUÑIZ RODRÍGUEZ, P.; LLORENTE AYALA, B.; GARCÍA-GONZÁLEZ, M.; COMA-DEL CORRAL, M. J.; GARCÍA GIRÓN, C. The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer. Molecular Biology Reports, v. 41, n. 4, p. 2275–2279, 2014. DOI: 10.1007/s11033-014-3072-4. PMID: 24481837.

3. CHOE, J.; YUN, J.; JEON, Y.; KIM, S. H.; PARK, G.; HUH, J. R.; OH, S.; KIM, J. E. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer, v. 14, n. 1, p. 335, 2014. DOI: 10.1186/1471-2407-14-335. PMID: 24885575.

4. CHUANG, S. C.; FANIDI, A.; UELAND, P. M. et al. Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention, v. 23, n. 3, p. 461–468, 2014. DOI: 10.1158/1055-9965.EPI-13-0664. PMID: 24399638.

5. CREELAN, B. C.; ANTONIA, S.; BEPLER, G.; GARRETT, T. J.; SIMON, G. R.; SOLIMAN, H. H. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small-cell lung cancer. OncoImmunology, v. 2, n. 3, e23428, 2013. DOI: 10.4161/onci.23428. PMID: 23894763.

6. EUSSEN, S. J. P. M.; UELAND, P. M.; VOLLSET, S. E.; NYGÅRD, O.; MIDTTUN, Ø.; SULO, G.; TELL, G. S. Kynurenines as predictors of acute coronary events in the Hordaland Health Study. International Journal of Cardiology, v. 189, p. 18–24, 2015. DOI: 10.1016/j.ijcard.2015.03.423. PMID: 25837723.

7. FERNS, D. M.; KEMA, I. P.; BUIST, M. R.; NIJMAN, H. W.; KENTER, G. G.; JORDANOVA, E. S. Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival. OncoImmunology, v. 4, n. 2, e981457, 2015. DOI: 10.4161/2162402X.2014.981457. PMID: 25949873.

8. FOLGIERO, V.; GOFFREDO, B. M.; FILIPPINI, P.; MASETTI, R.; BONANNO, G.; CARUSO, R.; BERTAINA, V.; MASTRONUZZI, A.; GASPARI, S.; ZECCA, M.; et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget, v. 5, n. 8, p. 2052–2064, 2014. DOI: 10.18632/oncotarget.1743. PMID: 24722251.

9. GUPTA, N. K.; THAKER, A. I.; KANURI, N.; RIEHL, T. E.; ROWLEY, C. W.; STENSON, W. F.; CIORBA, M. A. Serum analysis of tryptophan catabolism pathway: correlation with Crohn’s disease activity. Inflammatory Bowel Diseases, v. 18, n. 7, p. 1214–1220, 2012. DOI: 10.1002/ibd.21854. PMID: 21830277.

10. LOVE, A. C.; SCHWARTZ, I.; PETZKE, M. M. Induction of indoleamine 2,3-dioxygenase by Borrelia burgdorferi in human immune cells correlates with pathogenic potential. Journal of Leukocyte Biology, v. 97, n. 2, p. 379–390, 2015. DOI: 10.1189/jlb.1A0814-410RR. PMID: 25411462.

12. RISTAGNO, G.; LATINI, R.; VAAHERSALO, J.; MASSON, S.; KUROLA, J.; VARPULA, T.; LUcCHETTI, J.; FRACASSO, C.; GUISO, G.; MONTANELLI, A.; BARLERA, S.; GOBBI, M.; TIAINEN, M.; PETTILÄ, V.; SKRIFVARS, M. B.; FINNRESUSCI INVESTIGATORS. Early activation of the kynurenine pathway predicts early death and long-term outcome in patients resuscitated from out-of-hospital cardiac arrest. Journal of the American Heart Association, v. 3, e001094, 2014. DOI: 10.1161/JAHA.114.001094. PMID: 25037015.

13. SULO, G.; VOLLSET, S. E.; NYGÅRD, O.; MIDTTUN, Ø.; UELAND, P. M.; EUSSEN, S. J.; PEDERSEN, E. R.; TELL, G. S. Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. International Journal of Cardiology, v. 168, n. 2, p. 1435–1440, 2013. DOI: 10.1016/j.ijcard.2012.12.055. PMID: 23357186.

14. SUZUKI, Y.; SUDA, T.; ASADA, K.; MIWA, S.; SUZUKI, M.; FUJIE, M.; FURUHASHI, K.; NAKAMURA, Y.; INUI, N.; SHIRAI, T.; HAYAKAWA, H.; NAKAMURA, H.; CHIDA, K. Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis. Clinical and Vaccine Immunology, v. 19, n. 3, p. 436–442, 2012. DOI: 10.1128/CVI.05694-11. PMID: 22259280.

15. ZUO, H.; UELAND, P. M.; ULVIK, A.; EUSSEN, S. J. P. M.; VOLLSET, S. E.; NYGÅRD, O.; MIDTTUN, Ø.; THEOFYLAKTOPOULOU, D.; MEYER, K.; TELL, G. S. Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality. American Journal of Epidemiology, v. 183, n. 4, p. 249–258, 2016. DOI: 10.1093/aje/kwv242. PMID: 26823436.

16. MERINO, J. J.; CABAÑA-MUÑOZ, M. E.; TOLEDANO GASCA, A.; et al. Elevated systemic L-kynurenine/L-tryptophan ratio and increased IL-1β and chemokine (CX3CL1, MCP-1) proinflammatory mediators in patients with long-term titanium dental implants. Journal of Clinical Medicine, v. 8, n. 9, p. 1368, 2019. DOI: 10.3390/jcm8091368. PMID: 31547232.

17. REICHETZEDER, C.; HEUNISCH, F.; VON EINEM, G.; et al. Pre-interventional kynurenine predicts medium-term outcome after contrast media exposure due to coronary angiography. Kidney and Blood Pressure Research, v. 42, n. 2, p. 244–256, 2017. DOI: 10.1159/000477222. PMID: 28609773.

18. ZIMMER, P.; SCHMIDT, M. E.; PRENTZELL, M. T.; et al. Resistance exercise reduces kynurenine pathway metabolites in breast cancer patients undergoing radiotherapy. Frontiers in Oncology, v. 9, p. 962, 2019. DOI: 10.3389/fonc.2019.00962. PMID: 31681625.

IDO no Sangue

1. BRANDACHER, G.; HOELLER, E.; FUCHS, D.; WEISS, H. G. Chronic immune activation underlies morbid obesity: is IDO a key player. Current Drug Metabolism, v. 8, n. 3, p. 289–295, 2007.

4. CHUANG, S. C.; FANIDI, A.; UELAND, P. M.; et al. Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk. Cancer Epidemiology, Biomarkers & Prevention, v. 23, n. 3, p. 461–468, mar. 2014.

5. CREELAN, B. C.; ANTONIA, S.; BEPLER, G.; GARRETT, T. J.; SIMON, G. R.; SOLIMAN, H. H. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer. OncoImmunology, v. 2, n. 3, e23428, 2013.

8. FOLGIERO, V.; GOFFREDO, B. M.; FILIPPINI, P.; et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget, v. 5, n. 8, p. 2052–2064, 2014.

10. MOON, Y. W.; HAJJAR, J.; HWU, P.; NAING, A. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. Journal for ImmunoTherapy of Cancer, v. 3, n. 1, p. 51, 2015. doi:10.1186/s40425-015-0094-9.

11. PEDERSEN, E. R.; SVINGEN, G. F.; SCHARTUM-HANSEN, H.; UELAND, P. M.; EBBING, M.; NORDREHAUG, J. E.; et al. Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. European Heart Journal, v. 34, n. 34, p. 2689–2696, set. 2013.

12. PLATTEN, M.; VON KNEBEL DOEBERITZ, N.; OEZEN, I.; WICK, W.; OCHS, K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Frontiers in Immunology, v. 5, p. 673, 2015. doi:10.3389/fimmu.2014.00673.

13. RISTAGNO, G.; LATINI, R.; VAAHERSALO, J.; et al. Early activation of the kynurenine pathway predicts early death and long-term outcome in patients resuscitated from out-of-hospital cardiac arrest. Journal of the American Heart Association, v. 3, e001094, 2014.

14. SULO, G.; VOLLSET, S. E.; NYGÅRD, O.; MIDTTUN, Ø.; UELAND, P. M.; EUSSEN, S. J. P. M.; PEDERSEN, E. R.; TELL, G. S. Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. International Journal of Cardiology, v. 168, n. 2, p. 1435–1440, 30 set. 2013.

15. SUZUKI, Y.; SUDA, T.; ASADA, K.; MIWA, S.; SUZUKI, M.; FUJIE, M.; et al. Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis. Clinical and Vaccine Immunology, v. 19, n. 3, p. 436–442, mar. 2012.

16. VAN BAREN, N.; VAN DEN EYNDE, B. J. Tryptophan-degrading enzymes in tumoral immune resistance. Frontiers in Immunology, v. 6, p. 34, 2015. doi:10.3389/fimmu.2015.00034.

17. ZUO, H.; UELAND, P. M.; ULVIK, A.; EUSSEN, S. J. P. M.; VOLLSET, S. E.; NYGÅRD, O.; MIDTTUN, Ø.; THEOFYLAKTOPOULOU, D.; MEYER, K.; TELL, G. S. Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality. American Journal of Epidemiology, v. 183, n. 4, p. 249–258, 2016. doi:10.1093/aje/kwv242.

18. DEWI, D. L.; MOHAPATRA, S. R.; BLANCO CABAÑES, S.; et al. Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. OncoImmunology, 2017, p. 1–12. doi:10.1080/2162402X.2016.1274477.

DBS® Estresse Oxidativo

Nitrotirosina no Sangue

1. PELUFFO, G.; RADI, R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovascular Research, v. 75, n. 2, p. 291–302, 15 jul. 2007. DOI: 10.1016/j.cardiores.2007.04.024. PMID: 17555718.

2. GONSETTE, R. E. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. Journal of the Neurological Sciences, v. 274, n. 1–2, p. 48–53, 15 nov. 2008. DOI: 10.1016/j.jns.2008.06.029. PMID: 18617355.

3. ISCHIROPOULOS, H. Protein tyrosine nitration – an update. Archives of Biochemistry and Biophysics, v. 484, n. 2, p. 117–121, 15 abr. 2009. DOI: 10.1016/j.abb.2008.10.034. PMID: 18983902.

4. KÖSE, F. A.; SEZİŞ, M.; AKÇİÇEK, F.; PABUÇÇUOĞLU, A. Oxidative and nitrosative stress markers in patients on hemodialysis and peritoneal dialysis. Blood Purification, v. 32, n. 3, p. 202–208, jan. 2011. DOI: 10.1159/000328030. PMID: 21757847.

5. PICONI, L.; QUAGLIARO, L.; CERIELLO, A. Oxidative stress in diabetes. Clinical Chemistry and Laboratory Medicine, v. 41, n. 9, p. 1144–1149, set. 2003. DOI: 10.1515/CCLM.2003.177. PMID: 14598863.

6. GALIÑANES, M.; CASÓS, K.; BLASCO-LUCAS, A.; PERMANYER, E.; MÁÑEZ, R.; LE TOURNEAU, T.; BARQUINERO, J.; SCHWARTZ, S. Jr.; ROUSSEL, T. B. J. C.; FELLAH-HEBIA, I.; SÉNAGE, T.; EVANGELISTA, A.; BADANO, L. P.; RUIZ-MAJORAL, A.; GALLI, C.; PADLER-KARAVANI, V.; SOULILLOU, J. P.; VIDAL, X.; COZZI, E.; COSTA, C. Oxidative stress in structural valve deterioration: a longitudinal clinical study. Biomolecules, v. 12, n. 11, p. 1606, 31 out. 2022. DOI: 10.3390/biom12111606. PMID: 36358956; PMCID: PMC9687638.

7. WANG, J.; CHEN, Y.; YUAN, H.; ZHANG, X.; FEBBRAIO, M.; PAN, Y.; HUANG, S.; LIU, Z. Mitochondrial biogenesis disorder and oxidative damage promote refractory apical periodontitis in rat and human. International Endodontic Journal, v. 57, n. 9, p. 1326–1342, set. 2024. DOI: 10.1111/iej.14106. PMID: 38881187.

8. FAN, Q.; CHEN, L.; CHENG, S.; LI, F.; LAU, W. B.; WANG, L. F.; LIU, J. H. Aging aggravates nitrate-mediated ROS/RNS changes. Oxidative Medicine and Cellular Longevity, v. 2014, p. 1–9, 2014. DOI: 10.1155/2014/376515. PMID: 24790702; PMCID: PMC3981534.

DBS® Cardiovascular

LDL Oxidada no Sangue

1. VIERECK, V.; GRÜNDKER, C.; BLASCHKE, S.; NIEDERKLEINE, B.; CORSI, M. M.; DOGLIOTTI, G.; PEDRONI, F.; ERMETICI, F.; MALAVAZOS, A.; AMBROSI, B. ADMA: a possible role in obese patients. Poster P173 of the 6th World Congress on Hyperhomocysteinemia, Saarbrücken, Germany, June 5–9, 2007. Clinical Chemistry and Laboratory Medicine, v. 45, n. 5, 2007.

2. KOUBAA, N.; NAKBI, A.; SMAOUI, M.; ABID, N.; CHAABA, R.; ABID, M.; HAMMAMI, M. Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clinical Biochemistry, v. 40, n. 13–14, p. 1007–1014, 2007. DOI: 10.1016/j.clinbiochem.2007.05.018.

3. LICASTRO, F.; DOGLIOTTI, G.; GOI, G.; MALAVAZOS, A. E.; CHIAPPELLI, M.; CORSI, M. M. Oxidated low-density lipoproteins (oxLDL) and peroxides in plasma of Down syndrome patients. Archives of Gerontology and Geriatrics, v. 44, supl. 1, p. 225–232, 2007. DOI: 10.1016/j.archger.2007.01.031. PMID: 17350133.

4. PFÜTZNER, A.; KOST, I.; LÖBIG, M.; KNESOVIC, M.; ARMBRUSTER, F. P.; FORST, T. Clinical evaluation of a new ELISA method for determination of oxidized LDL particles – a potential marker for arteriosclerotic risk in diabetes mellitus. Abstract of the 5th Diabetes Technology Meeting, San Francisco, EUA, 10–12 nov. 2005.

5. NAJAFI, M.; ROUSTAZADEH, A.; ALIPOOR, B. Ox-LDL particles: modified components, cellular uptake, biological roles and clinical assessments. Cardiovascular & Hematological Disorders – Drug Targets, v. 11, n. 2, p. 119–128, 2011. DOI: 10.2174/187152911798346990. PMID: 22044040.

NeuroStress®

Histamina na Urina

1. BARATA-ANTUNES, S.; et al. Dual role of histamine on microglia-induced neurodegeneration. Biochimica et Biophysica Acta – Molecular Basis of Disease, v. 1863, n. 3, p. 764–769, 2017. DOI: 10.1016/j.bbadis.2016.12.012. PMID: 28024976.

2. WORM, J.; FALKENBERG, K.; OLESEN, J. Histamine and migraine revisited: mechanisms and possible drug targets. Journal of Headache and Pain, v. 20, n. 1, p. 30, 2019. DOI: 10.1186/s10194-019-0983-2. PMID: 30902007.

3. YAMAUCHI, K.; OGASAWARA, M. The role of histamine in the pathophysiology of asthma and the clinical efficacy of antihistamines in asthma therapy. International Journal of Molecular Sciences, v. 20, n. 7, p. 1733, 2019. DOI: 10.3390/ijms20071733. PMID: 30917520.

4. HU, W.; CHEN, Z. The roles of histamine and its receptor ligands in central nervous system disorders: an update. Pharmacology & Therapeutics, v. 175, p. 116–132, 2017. DOI: 10.1016/j.pharmthera.2017.02.039. PMID: 28235411.

5. BRANCO, A.; et al. Role of histamine in modulating the immune response and inflammation. Mediators of Inflammation, v. 2018, p. 9524075, 2018. DOI: 10.1155/2018/9524075. PMID: 30105147.

6. FERSTL, R.; AKDIS, C. A.; O’MAHONY, L. Histamine regulation of innate and adaptive immunity. Frontiers in Bioscience (Landmark Edition), v. 17, p. 40–53, 2012. DOI: 10.2741/3915. PMID: 22201714.

7. HUNGERFORD, J. M. Scombroid poisoning: a review. Toxicon, v. 56, n. 2, p. 231–243, 2010. DOI: 10.1016/j.toxicon.2010.02.006. PMID: 20167207.

8. SMUDA, C.; BRYCE, P. J. New developments in the use of histamine and histamine receptors. Current Allergy and Asthma Reports, v. 11, n. 2, p. 94–100, 2011. DOI: 10.1007/s11882-010-0169-4. PMID: 21188535.

9. PINI, A.; et al. Histamine and diabetic nephropathy: an up-to-date overview. Clinical Science (London), v. 133, n. 1, p. 41–54, 2019. DOI: 10.1042/CS20180380. PMID: 30463924.

10. SCAMMELL, T. E.; et al. Histamine: neural circuits and new medications. Sleep, v. 42, n. 1, p. zsy183, 2019. DOI: 10.1093/sleep/zsy183. PMID: 30289480.

11. YUAN, H.; SILBERSTEIN, S. D. Histamine and migraine. Headache: The Journal of Head and Face Pain, v. 58, n. 1, p. 184–193, 2018. DOI: 10.1111/head.13224. PMID: 29338063.

12. THANGAM, E. B.; et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Frontiers in Immunology, v. 9, p. 1873, 2018. DOI: 10.3389/fimmu.2018.01873. PMID: 30123112.

13. LIEBERMAN, P. The basics of histamine biology. Annals of Allergy, Asthma & Immunology, v. 106, n. 2, supl., p. S2–S5, 2011. DOI: 10.1016/j.anai.2010.10.015. PMID: 21277557.

14. SAN MAURO MARTIN, I.; BRACHERO, S.; GARICANO VILAR, E. Histamine intolerance and dietary management: a complete review. Allergologia et Immunopathologia (Madrid), v. 44, n. 5, p. 475–483, 2016. DOI: 10.1016/j.aller.2016.01.003. PMID: 26948628.

Serotonina na Urina

1. CHOJNACKI, C.; et al. Evaluation of serotonin and dopamine secretion and metabolism in patients with irritable bowel syndrome. Polish Archives of Internal Medicine, v. 128, n. 11, p. 711–713, 2018. DOI: 10.20452/pamw.4355. PMID: 30462679.

2. HUANG, H.; CHEN, Z.; YAN, X. Simultaneous determination of serotonin and creatinine in urine by combining two ultrasound-assisted emulsification microextractions with on-column stacking in capillary electrophoresis. Journal of Separation Science, v. 35, n. 3, p. 436–444, 2012. DOI: 10.1002/jssc.201100802. PMID: 22213402.

3. PIEŠŤANSKÝ, J.; MARÁKOVÁ, K.; MIKUŠ, P. Two-dimensional capillary electrophoresis with on-line sample preparation and cyclodextrin separation environment for direct determination of serotonin in human urine. Molecules, v. 22, n. 10, p. 1671, 2017. DOI: 10.3390/molecules22101671. PMID: 29048389.

4. BIEGER, W. P. NeuroStress Guide. 2011.

5. LINDSTRÖM, M.; et al. Comparison of serum serotonin and serum 5-HIAA LC-MS/MS assays in the diagnosis of serotonin-producing neuroendocrine neoplasms: a pilot study. Clinica Chimica Acta, v. 482, p. 78–83, 2018. DOI: 10.1016/j.cca.2018.03.029. PMID: 29602032.

6. REN, C.; et al. Low levels of serum serotonin and amino acids identified in migraine patients. Biochemical and Biophysical Research Communications, v. 496, n. 2, p. 267–273, 2018. DOI: 10.1016/j.bbrc.2018.01.018. PMID: 29331788.

7. MORIARTY, M.; et al. Development of an LC-MS/MS method for the analysis of serotonin and related compounds in urine and the identification of a potential biomarker for attention deficit hyperactivity/hyperkinetic disorder. Analytical and Bioanalytical Chemistry, v. 401, n. 8, p. 2481–2493, 2011. DOI: 10.1007/s00216-011-5291-0. PMID: 21833672.

8. NICHKOVA, M. I.; et al. Evaluation of a novel ELISA for serotonin: urinary serotonin as a potential biomarker for depression. Analytical and Bioanalytical Chemistry, v. 402, n. 4, p. 1593–1600, 2012. DOI: 10.1007/s00216-011-5540-2. PMID: 22193294.

9. HOLCK, A.; et al. Plasma serotonin levels are associated with antidepressant response to SSRIs. Journal of Affective Disorders, v. 250, p. 65–70, 2019. DOI: 10.1016/j.jad.2019.02.059. PMID: 30877732.

10. JAWOREK, A. K.; et al. Depression and serum content of serotonin in adult patients with atopic dermatitis. Advances in Experimental Medicine and Biology, v. 1271, p. 83–88, 2020. DOI: 10.1007/5584_2020_526. PMID: 32207040.

11. SHU, B.; et al. Serotonin and YAP/VGLL4 balance correlated with progression and poor prognosis of hepatocellular carcinoma. Scientific Reports, v. 8, n. 1, p. 9739, 2018. DOI: 10.1038/s41598-018-28152-6. PMID: 29930124.

12. MAHATO, K.; et al. Novel electrochemical biosensor for serotonin detection based on gold nanorattles decorated reduced graphene oxide in biological fluids and in vitro model. Biosensors and Bioelectronics, v. 142, p. 111502, 2019. DOI: 10.1016/j.bios.2019.111502. PMID: 31327583.

13. YU, R. High serum serotonin test results caused by traumatic vascular access due to difficult veins. Pancreas, v. 48, n. 6, p. e51–e53, 2019. DOI: 10.1097/MPA.0000000000001324. PMID: 31206341.

14. MAMDOUH, F.; et al. Serum serotonin as a potential diagnostic marker for hepatocellular carcinoma. Journal of Interferon & Cytokine Research, v. 39, n. 12, p. 780–785, 2019. DOI: 10.1089/jir.2019.0051. PMID: 31826762.

Dopamina na Urina

1. BIEGER, W. P. NeuroStress Guide. 2011.

2. EISENHOFER, G.; et al. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacological Reviews, v. 56, n. 3, p. 331–349, 2004. DOI: 10.1124/pr.56.3.1. PMID: 15317907.

3. DANTZER, R.; O’CONNOR, J. C.; FREUND, G. G.; JOHNSON, R. W.; KELLEY, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience, v. 9, n. 1, p. 46–57, 2008. DOI: 10.1038/nrn2297. PMID: 18073775.

4. DI MICHELE, F.; PISANI, A.; MARTORANA, A.; PANTALONE, M.; BERNARDI, G.; STEFANO, V. D.; PLACIDI, F. Neurosteroid and neurotransmitter alterations in Parkinson’s disease. Frontiers in Neuroendocrinology, v. 34, n. 2, p. 132–142, 2013. DOI: 10.1016/j.yfrne.2013.01.002. PMID: 23376065.

5. FLINT, J.; KENDLER, K. S. The genetics of major depression. Neuron, v. 81, n. 3, p. 484–503, 2014. DOI: 10.1016/j.neuron.2014.01.027. PMID: 24507187.

6. MARC, D. T.; ABOU-ZEID, D. M.; RIES, C. R.; KAVANAGH, M.; FITZGERALD, P.; SAUCIER, D. M. Neurotransmitters excreted in the urine as biomarkers of nervous system activity: validity and clinical applicability. Neuroscience & Biobehavioral Reviews, v. 35, n. 3, p. 635–644, 2011. DOI: 10.1016/j.neubiorev.2010.07.007. PMID: 20688148.

7. KIM, H.; et al. Vitamin C prevents stress-induced damage on the heart caused by the death of cardiomyocytes, through down-regulation of the excessive production of catecholamine, TNF-α, and ROS production in Gulo(-/-)Vit C-insufficient mice. Free Radical Biology & Medicine, v. 65, p. 573–583, 2013. DOI: 10.1016/j.freeradbiomed.2013.07.015. PMID: 23872051.

8. BADA, A. A.; et al. Peripheral vasodilatation determines cardiac output in exercising humans: insight from atrial pacing. Journal of Physiology, v. 590, n. 8, p. 2051–2060, 2012. DOI: 10.1113/jphysiol.2011.225680. PMID: 22310365.

9. PARKS, C. G.; et al. Employment and work schedule are related to telomere length in women. Occupational and Environmental Medicine, v. 68, n. 8, p. 582–589, 2011. DOI: 10.1136/oem.2010.060020. PMID: 21273220.

10. EISENHOFER, G.; PAMPORAKI, C.; LENDERS, J. W. M. Biochemical assessment of pheochromocytoma and paraganglioma. Endocrine Reviews, v. 44, n. 5, p. 862–909, 2023. DOI: 10.1210/endrev/bnad013. PMID: 37367854.

GABA na Urina

1. BIEGER, W. P. NeuroStress Guide. 2011.

2. BUSTILLO, J. R. Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update. Dialogues in Clinical Neuroscience, v. 15, n. 3, p. 329–337, 2013. PMID: 24174902.

3. STREETER, C. C.; GERBARG, P. L.; SAPER, R. B.; CIRAULO, D. A.; BROWN, R. P. Effects of yoga on the autonomic nervous system, gamma-aminobutyric acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder. Medical Hypotheses, v. 78, n. 5, p. 571–579, maio 2012. DOI: 10.1016/j.mehy.2012.01.021. PMID: 22365651.

4. DUMAN, R. S.; SANACORA, G.; KRYSTAL, J. H. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron, v. 102, n. 1, p. 75–90, 2019. DOI: 10.1016/j.neuron.2019.03.013. PMID: 30946828.

5. FEMENÍA, T.; et al. Dysfunctional hippocampal activity affects emotion and cognition in mood disorders. Brain Research, v. 1476, p. 58–70, 2012. DOI: 10.1016/j.brainres.2012.01.073. PMID: 22353420.

6. FLASNOECKER, M. Reise aus dem Stress – Körper, Geist und Psyche stärken. München: W. Zuckschwerdt Verlag GmbH, 2015.

7. FRISARDI, V.; PANZA, F.; FAROOQUI, A. A. Late-life depression and Alzheimer’s disease: the glutamatergic system inside of this mirror relationship. Brain Research Reviews, v. 67, n. 1–2, p. 344–355, 2011. DOI: 10.1016/j.brainresrev.2011.03.003. PMID: 21406234.

8. GAO, S. F.; BAO, A. M. Corticotropin-releasing hormone, glutamate, and γ-aminobutyric acid in depression. The Neuroscientist, v. 17, n. 1, p. 124–144, 2011. DOI: 10.1177/1073858409355831. PMID: 20511232.

9. HARRIS, R. E.; CLAUW, D. J. Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy. Neuroscience Letters, v. 520, n. 2, p. 192–196, 2012. DOI: 10.1016/j.neulet.2012.03.042. PMID: 22465236.

10. KENDELL, S. F.; KRYSTAL, J. H.; SANACORA, G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion on Therapeutic Targets, v. 9, n. 1, p. 153–168, 2005. DOI: 10.1517/14728222.9.1.153. PMID: 15725065.

11. KRYSTAL, J. H.; et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry, v. 7, supl. 1, p. S71–S80, 2002. DOI: 10.1038/sj.mp.4001021. PMID: 11986998.

12. LENER, M. S.; et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biological Psychiatry, v. 81, n. 10, p. 886–897, 2017. DOI: 10.1016/j.biopsych.2016.05.005. PMID: 27288712.

13. SANACORA, G.; TRECCANI, G.; POPOLI, M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology, v. 62, n. 1, p. 63–77, 2012. DOI: 10.1016/j.neuropharm.2011.07.036. PMID: 21827775.

14. STRIENZ, J. Nebennierenunterfunktion – Stress stört die Hormonbalance. 3. ed. München: W. Zuckschwerdt Verlag, 2019.

Glutamato na Urina

1. BIEGER, W. P. NeuroStress Guide. 2011.

3. DUMAN, R. S.; SANACORA, G.; KRYSTAL, J. H. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron, v. 102, n. 1, p. 75–90, 2019. DOI: 10.1016/j.neuron.2019.03.013. PMID: 30946828.

4. FEMENÍA, T.; et al. Dysfunctional hippocampal activity affects emotion and cognition in mood disorders. Brain Research, v. 1476, p. 58–70, 2012. DOI: 10.1016/j.brainres.2012.01.073. PMID: 22353420.

5. FLASNOECKER, M. Reise aus dem Stress – Körper, Geist und Psyche stärken. München: W. Zuckschwerdt Verlag GmbH, 2015.

6. FRISARDI, V.; PANZA, F.; FAROOQUI, A. A. Late-life depression and Alzheimer’s disease: the glutamatergic system inside of this mirror relationship. Brain Research Reviews, v. 67, n. 1–2, p. 344–355, 2011. DOI: 10.1016/j.brainresrev.2011.03.003. PMID: 21406234.

7. GAO, S. F.; BAO, A. M. Corticotropin-releasing hormone, glutamate, and γ-aminobutyric acid in depression. The Neuroscientist, v. 17, n. 1, p. 124–144, 2011. DOI: 10.1177/1073858409355831. PMID: 20511232.

8. HARRIS, R. E.; CLAUW, D. J. Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy. Neuroscience Letters, v. 520, n. 2, p. 192–196, 2012. DOI: 10.1016/j.neulet.2012.03.042. PMID: 22465236.

9. KENDELL, S. F.; KRYSTAL, J. H.; SANACORA, G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion on Therapeutic Targets, v. 9, n. 1, p. 153–168, 2005. DOI: 10.1517/14728222.9.1.153. PMID: 15725065.

10. KRYSTAL, J. H.; et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry, v. 7, supl. 1, p. S71–S80, 2002. DOI: 10.1038/sj.mp.4001021. PMID: 11986998.

11. LENER, M. S.; et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biological Psychiatry, v. 81, n. 10, p. 886–897, 2017. DOI: 10.1016/j.biopsych.2016.05.005. PMID: 27288712.

12. SANACORA, G.; TRECCANI, G.; POPOLI, M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology, v. 62, n. 1, p. 63–77, 2012. DOI: 10.1016/j.neuropharm.2011.07.036. PMID: 21827775.

13. STRIENZ, J. Nebennierenunterfunktion – Stress stört die Hormonbalance. 3. ed. München: W. Zuckschwerdt Verlag, 2019.

Adrenalina na Urina

1. BIEGER, W. P. NeuroStress Guide. 2011.

5. FLINT, J.; KENDLER, K. S. The genetics of major depression. Neuron, v. 81, n. 3, p. 484–503, 2014. DOI: 10.1016/j.neuron.2014.01.027. PMID: 24507187.

7. KIM, H.; et al. Vitamin C prevents stress-induced damage on the heart caused by the death of cardiomyocytes, through down-regulation of the excessive production of catecholamine, TNF-α, and ROS production in Gulo(-/-)Vit C-insufficient mice. Free Radical Biology and Medicine, v. 65, p. 573–583, 2013. DOI: 10.1016/j.freeradbiomed.2013.07.015. PMID: 23872051.

8. BADA, A. A.; et al. Peripheral vasodilatation determines cardiac output in exercising humans: insight from atrial pacing. The Journal of Physiology, v. 590, n. 8, p. 2051–2060, 2012. DOI: 10.1113/jphysiol.2011.225680. PMID: 22310365.

Noradrenalina na Urina

1. BIEGER, W. P. NeuroStress Guide. 2011.

5. FLINT, J.; KENDLER, K. S. The genetics of major depression. Neuron, v. 81, n. 3, p. 484–503, 2014. DOI: 10.1016/j.neuron.2014.01.027. PMID: 24507187.

7. KIM, H.; et al. Vitamin C prevents stress-induced damage on the heart caused by the death of cardiomyocytes, through down-regulation of the excessive production of catecholamine, TNF-α, and ROS production in Gulo(-/-)Vit C-insufficient mice. Free Radical Biology and Medicine, v. 65, p. 573–583, 2013. DOI: 10.1016/j.freeradbiomed.2013.07.015. PMID: 23872051.

SalivaCare®

Cortisol na Saliva

1. FRIES, E.; DETTENBORN, L.; KIRSCHBAUM, C. The cortisol awakening response (CAR): facts and future directions. International Journal of Psychophysiology, v. 72, n. 1, p. 67–73, 2009. DOI: 10.1016/j.ijpsycho.2008.03.014. PMID: 18854200.

2. HEILHAMMER, O. H.; et al. Salivary cortisol as a biomarker in stress research. Psychoneuroendocrinology, v. 34, n. 2, p. 163–171, 2009. DOI: 10.1016/j.psyneuen.2008.08.004. PMID: 18842346.

3. McEWEN, B. S. Central effects of stress hormones in health and disease: understanding the protective and damaging effects of stress and stress mediators. European Journal of Pharmacology, v. 583, p. 174–185, 2008. DOI: 10.1016/j.ejphar.2007.11.071. PMID: 18282566.

4. MILLER, G. E.; CHEN, E.; ZHOU, E. S. Greater inflammatory activity and blunted glucocorticoid signalling in monocytes of chronically stressed caregivers. Brain, Behavior, and Immunity, v. 41, p. 191–199, 2014. DOI: 10.1016/j.bbi.2014.05.016. PMID: 24929388.

5. OSTERBERG, K.; KARLSON, B.; HANSSON, M. J.; BALDWIN, D. S.; NAESLUND, J.; ORBAEK, P. Cognitive performance in patients with burnout, in relation to diurnal salivary cortisol. Stress, v. 12, n. 1, p. 70–81, 2009. DOI: 10.1080/10253890802042037. PMID: 19065465.

6. FLEINER, T.; ZIJLSTRA, W.; DAUTH, H.; HAUSSERMANN, P. Evaluation of a hospital-based day-structuring exercise programme on exacerbated behavioural and psychological symptoms in dementia – the exercise carrousel: study protocol for a randomised controlled trial. BMC Geriatrics, v. 16, p. 228, 2015. DOI: 10.1186/s12877-016-0384-7.

7. DE STEENWINKEL, F. D. O.; HOKKEN-KOELEGA, A. C. S.; HAZES, J. M. W.; DOLHAIN, R. J. E. M. The influence of foetal prednisone exposure on the cortisol level in the offspring. Clinical Endocrinology, v. 80, p. 804–810, 2014. DOI: 10.1111/cen.12386. PMID: 24188636.

8. BALSALOBRE-FERNÁNDEZ, C.; TJERO-GONZÁLEZ, C. M.; DEL CAMPO-VECINO, J. Relationships between training load, salivary cortisol responses and performance during season training in middle- and long-distance runners. PLOS ONE, v. 9, n. 8, e104613, 2014. DOI: 10.1371/journal.pone.0104613.

9. NIEMAN, L. K.; BILLER, B. M. K.; FINDLING, J. W.; NEWELL-PRICE, J.; MONTORI, V. M. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, v. 93, n. 5, p. 1526–1540, 2008. DOI: 10.1210/jc.2008-0125. PMID: 18334580.

10. KIRSCHBAUM, C.; HELLHAMMER, D. H. Salivary cortisol in psychobiological research: an overview. Neuropsychobiology, v. 22, p. 150–169, 1989. DOI: 10.1159/000118611. PMID: 2485862.

11. KIRSCHBAUM, C.; HELLHAMMER, D. H. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology, v. 19, p. 313–333, 1994. DOI: 10.1016/0306-4530(94)90013-2. PMID: 8047637.

12. VINING, R. F.; et al. Salivary cortisol: a better measure of adrenal cortical function than serum cortisol. Annals of Clinical Biochemistry, v. 20, p. 329–335, 1983. DOI: 10.1177/000456328302000601. PMID: 6310800.

13. DORN, L. D.; LUCKE, J. F.; LOUCKS, T. L.; BERGA, S. L. Salivary cortisol reflects serum cortisol: analysis of circadian profiles. Annals of Clinical Biochemistry, v. 44, p. 281–284, 2007. DOI: 10.1258/000456307780480954. PMID: 17456274.

14. AARDAL, E.; HOLM, A. C. Cortisol in saliva – reference ranges and relation to cortisol in serum. European Journal of Clinical Chemistry and Clinical Biochemistry, v. 33, p. 927–932, 1995. PMID: 8753141.

15. GARDE, A. H.; HANSEN, A. M. Long-term stability of salivary cortisol. Scandinavian Journal of Clinical and Laboratory Investigation, v. 65, p. 433–436, 2005. DOI: 10.1080/00365510510025773. PMID: 16081383.

Melatonina na Saliva

1. KOORENGEVEL, K. M.; et al. A forced desynchrony study of circadian pacemaker characteristics in seasonal affective disorder. Journal of Biological Rhythms, v. 17, p. 463–475, 2002. DOI: 10.1177/0748730402238238. PMID: 12375606.

2. WIRZ-JUSTICE, A.; et al. No evidence for a phase delay in human circadian rhythms after a single morning melatonin administration. Journal of Pineal Research, v. 32, n. 1, p. 1–5, 2002. DOI: 10.1034/j.1600-079x.2002.10836.x. PMID: 11841580.

3. GRAW, P.; et al. Early morning melatonin administration impairs psychomotor vigilance. Behavioural Brain Research, v. 121, n. 1–2, p. 167–172, 2001. DOI: 10.1016/s0166-4328(00)00391-4. PMID: 11275294.

4. DANILENKO, K. V.; et al. Is sleep per se a Zeitgeber in humans? Journal of Biological Rhythms, v. 18, p. 170–178, 2003. DOI: 10.1177/0748730402259962. PMID: 12693869.

5. VAUGHAN, G. M. New sensitive serum melatonin radioimmunoassay employing the Kennaway G280 antibody: Syrian hamster morning adrenergic response. Journal of Pineal Research, v. 15, p. 88–103, 1993. DOI: 10.1111/j.1600-079x.1993.tb00504.x. PMID: 8282970.

6. VOULTSIOS, A.; KENNEDY, G. A.; DAWSON, D. Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin. Journal of Biological Rhythms, v. 12, n. 5, p. 457–466, 1997. DOI: 10.1177/074873049701200507. PMID: 9376644.

DHEA na Saliva

1. MANNINGER, N.; KÜHN, S.; KUNZEL, H. E.; SCHLATT, S.; WÜST, S.; et al. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Frontiers in Neuroendocrinology, v. 30, p. 65–91, 2009. DOI: 10.1016/j.yfrne.2008.11.002. PMID: 19063968.

2. GALLAGHER, P.; LEITCH, M. M.; MASSEY, A. E.; McALLISTER-WILLIAMS, R. H.; YOUNG, A. H. Assessing cortisol and dehydroepiandrosterone (DHEA) in saliva: effects of collection method. Journal of Psychopharmacology, v. 20, n. 5, p. 643–649, 2006. DOI: 10.1177/0269881106060585. PMID: 16401662.

3. WHEMBOLOUA, G. L.; GRANGER, D. A.; SINGER, S.; KIVLIGHAN, K. T.; MARGUIN, J. A. Bacteria in the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva. Hormones and Behavior, v. 49, n. 4, p. 478–483, 2006. DOI: 10.1016/j.yhbeh.2005.09.008. PMID: 16289371.

4. WOOD, P. Salivary steroid assays – research or routine? Annals of Clinical Biochemistry, v. 46, n. 3, p. 183–196, 2009. DOI: 10.1258/acb.2009.009001. PMID: 19304724.

5. LABRIE, F.; LUU-THE, V.; BELANGER, A.; LIN, S. X.; SIMARD, J.; PELLETIER, G.; LABRIE, C. Is dehydroepiandrosterone a hormone? Journal of Endocrinology, v. 187, n. 2, p. 169–196, 2005. DOI: 10.1677/joe.1.06264. PMID: 16214946.

6. CARLSTRÖM, K.; BRODY, S.; LUNELL, N. O.; LAGRELIUS, A.; MÖLLERSTRÖM, G.; POUSETTE, A.; RANNEVIK, G.; STEGE, R.; VON SCHOULTZ, B. Dehydroepiandrosterone sulphate and dehydroepiandrosterone in serum: differences related to age and sex. Maturitas, v. 10, n. 4, p. 297–306, 1988. DOI: 10.1016/0378-5122(88)90003-7. PMID: 3141641.

7. RAINEY, W. E.; NAKAMURA, Y. Regulation of adrenal androgen biosynthesis. Journal of Steroid Biochemistry and Molecular Biology, v. 108, n. 3–5, p. 281–286, 2008. DOI: 10.1016/j.jsbmb.2007.09.015. PMID: 17945481.

8. THOMAS, L. Labor und Diagnose – Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik. 8. Auflage. Frankfurt/Main: TH-Books Verlagsgesellschaft, 2012.

9. MARKS, V. False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. Clinical Chemistry, v. 48, n. 11, p. 2008–2016, 2002. PMID: 12406973.

10. TATE, J.; WARD, G. Interferences in immunoassays. Clinical Biochemist Reviews, v. 25, p. 105–120, maio 2004. PMID: 18458713.

11. SELBY, C. Interference in immunoassays. Annals of Clinical Biochemistry, v. 36, p. 704–721, 1999. DOI: 10.1177/000456329903600603. PMID: 10672372.

Sulfato de DHEA na Saliva

2. JOSHI, U. M.; et al. Steroids, v. 34, n. 1, p. 35–42, 1979. DOI: 10.1016/0039-128x(79)90007-9.

3. TURKES, A.; et al. Journal of Endocrinology, v. 81, n. 2, p. P165, 1979. DOI: 10.1677/joe.0.081p165.

4. ISMAIL, A. A.; et al. Journal of Clinical Endocrinology and Metabolism, v. 34, p. 177–184, 1972. DOI: 10.1210/jcem-34-2-177. PMID: 4536227.

5. RAJKOWSKI, K. M.; et al. Steroids, v. 29, n. 5, p. 621–630, 1977. DOI: 10.1016/0039-128x(77)90022-3.

6. WISDOM, G. B. Enzyme-immunoassay for steroid hormones: analytical and clinical applications. Clinical Chemistry, v. 22, n. 8, p. 1243–1255, 1976. PMID: 786229.

7. ABRAHAM, G. E.; et al. Ovarian and adrenal contribution to the production of androgens and estrogens in normal women and in women with adrenal hyperplasia. Obstetrics and Gynecology, v. 47, n. 4, p. 395–402, 1976. DOI: 10.1097/00006250-197604000-00002.

8. ABRAHAM, G. E.; et al. Radioimmunoassay of plasma progesterone. Obstetrics and Gynecology, v. 53, n. 1, p. 111–115, 1979. DOI: 10.1097/00006250-197901000-00020.

9. HOPPER, B. R.; et al. Radioimmunoassay for dehydroepiandrosterone sulfate. Journal of Clinical Endocrinology and Metabolism, v. 40, n. 3, p. 458–467, 1975. DOI: 10.1210/jcem-40-3-458.

10. WINTER, J. S. D.; et al. Gonadal steroidogenesis during human development: new observations. Clinical Obstetrics and Gynecology, v. 21, n. 1, p. 67–79, 1978. DOI: 10.1097/00003081-197803000-00007.

11. RIAD, D. Steroid biosynthesis and metabolism. Endocrine Reviews, v. 3, n. 4, p. 304–367, 1978. DOI: 10.1210/edrv-3-4-304.

IgA Secretora na Saliva

1. TOMASI, T. B. Jr. The Immune System of Secretions. Englewood Cliffs, New Jersey: Prentice-Hall Inc., 1976. 161 p. ISBN 9780134516097.

2. BEN-ARYEH, H.; FISHER, M.; SZARGEL, R.; LAUFER, D. Composition of whole unstimulated saliva of healthy children: changes with age. Archives of Oral Biology, v. 35, n. 11, p. 929–931, 1990. DOI: 10.1016/0003-9969(90)90075-L. PMID: 1704211.

3. SMITH, D. J.; TAUBMAN, M. A.; EBERSOLE, J. L. Ontogeny and senescence of salivary immunity. Journal of Dental Research, v. 66, n. 2, p. 451–456, 1987. DOI: 10.1177/00220345870660021101. PMID: 3040823.

4. VENTURA, M. T. Evaluation of IgA1-IgA2 levels in serum and saliva of young and elderly people. Allergologia et Immunopathologia (Madr.), v. 19, n. 5, p. 183–185, 1991. PMID: 1811413.

5. KUGLER, J.; HESS, M.; HAAKE, D. Secretion of salivary immunoglobulin A in relation to age, saliva flow, mood states, secretion of albumin, cortisol, and catecholamines in saliva. Journal of Clinical Immunology, v. 12, n. 1, p. 45–49, 1992. DOI: 10.1007/BF00918272. PMID: 1551941.

6. JEMMOTT, J. B. 3rd; McCLELLAND, D. C. Secretory IgA as a measure of resistance to infectious disease: comments on Stone, Cox, Valdimarsdottir, and Neale. Behavioral Medicine, v. 15, n. 2, p. 63–71, 1989. DOI: 10.1080/08964289.1989.9935153. PMID: 2663100.

7. GREGORY, R. L.; KIM, D. E.; KINDLE, J. C.; HOBBS, L. C.; LLOYD, D. R. Immunoglobulin-degrading enzymes in localized juvenile periodontitis. Journal of Periodontal Research, v. 27, n. 3, p. 176–183, 1992. DOI: 10.1111/j.1600-0765.1992.tb01666.x. PMID: 1318974.

8. RUAN, M. S. [The relation of secretory IgA and caries]. Zhonghua Kou Qiang Yi Xue Za Zhi, v. 25, n. 3, p. 158–160, 190, 1990. (Em chinês). PMID: 2120009.

9. JEMMOTT, J. B. 3rd; MAGLOIRE, K. Academic stress, social support, and secretory immunoglobulin A. Journal of Personality and Social Psychology, v. 55, n. 5, p. 803–810, 1988. DOI: 10.1037/0022-3514.55.5.803. PMID: 3210147.

10. KUGLER, J. Emotionale Befindlichkeit und Immunglobulin A im Speichel – Eine Literaturübersicht [Emotional status and immunoglobulin A in saliva – review of the literature]. Psychotherapie Psychosomatik Medizinische Psychologie, v. 41, n. 6, p. 232–242, 1991. (Em alemão). PMID: 1886976.

11. SHIRTCLIFF, E. A.; GRANGER, D. A.; SCHWARTZ, E.; CURRAN, M. J. Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results. Psychoneuroendocrinology, v. 26, n. 2, p. 165–173, 2001. DOI: 10.1016/S0306-4530(00)00042-1. PMID: 11087962.

12. EALICK, S. E. (Ed.) An Introduction to Radioimmunoassay and Related Techniques. 5th ed. (Volume 6). Amsterdam: Elsevier, 1995.

13. WESTGARD, J. O. Basic Quality Control Practices. Online course. Disponível em: http://www.westgard.com.

14. BOSCATO, L. M.; STUART, M. C. Heterophilic antibodies: a problem for all immunoassays. Clinical Chemistry, v. 34, p. 27–33, 1988. PMID: 3122285.

Estradiol na Saliva

1. TSANG, B. K.; et al. Steroid biosynthesis by isolated human ovarian follicular cells in vitro. Journal of Clinical Endocrinology and Metabolism, v. 51, p. 1407–1411, 1980. DOI: 10.1210/jcem-51-6-1407.

2. GORE-LANGTON, R. E.; ARMSTRONG, D. T. Follicular steroidogenesis and its control. In: KNOBIL, E.; NEILL, J. D. (Eds.). The Physiology of Reproduction. New York: Raven Press, 1988. p. 331–385.

3. HALL, P. F. Steroid synthesis: organization and regulation. In: KNOBIL, E.; NEILL, J. D. (Eds.). The Physiology of Reproduction. New York: Raven Press, 1988. p. 975–988.

4. SALDANHA, C. J.; REMAGE-HEALEY, L.; SCHLINGER, B. A. Synaptocrine signaling: steroid synthesis and action at the synapse. Endocrine Reviews, v. 32, n. 4, p. 532–549, 2011. DOI: 10.1210/er.2011-0004.

5. WU, C. H.; et al. Free and protein-bound plasma estradiol-17β during the menstrual cycle. Journal of Clinical Endocrinology and Metabolism, v. 43, n. 2, p. 436–445, 1976. DOI: 10.1210/jcem-43-2-436.

6. FOX, E. M.; et al. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids, v. 74, n. 7, p. 622–627, 2009. DOI: 10.1016/j.steroids.2008.12.013.

7. FERNANDO, R. I.; et al. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Molecular Biology of the Cell, v. 15, n. 7, p. 3266–3284, 2004. DOI: 10.1091/mbc.e03-11-0852.

8. BOVENKERK, S.; et al. Induction of p53 expression and function by estrogen in osteoblasts. Calcified Tissue International, v. 73, n. 3, p. 274–280, 2003. DOI: 10.1007/s00223-002-2120-y.

9. VAZQUEZ RODRIGUEZ, G.; et al. Estradiol promotes breast cancer cell migration via recruitment and activation of neutrophils. Cancer Immunology Research, v. 5, n. 3, p. 234–247, 2017. DOI: 10.1158/2326-6066.CIR-16-0184.

10. LINTON, L.; et al. Associations of serum levels of sex hormones in follicular and luteal phases of the menstrual cycle with breast tissue characteristics in young women. PLoS ONE, v. 11, n. 10, e0163865, 2016. DOI: 10.1371/journal.pone.0163865.

11. KIM, J. Y.; et al. Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer, v. 13, p. 503, 2013. DOI: 10.1186/1471-2407-13-503.

12. FARAHANI, H.; et al. Serum and saliva levels of cancer antigen 15-3, carcinoembryonic antigen, estradiol, vaspin, and obestatin as biomarkers for the diagnosis of breast cancer in postmenopausal women. Laboratory Medicine, v. 51, p. 620–627, 2020. DOI: 10.1093/labmed/lmaa046.

13. SIITERI, P. K.; et al. The serum transport of steroid hormones. Recent Progress in Hormone Research, v. 38, p. 457–510, 1982. DOI: 10.1016/b978-0-12-571138-9.50016-8.

14. MARTIN, B.; et al. Binding of steroids by proteins in follicular fluid of the human ovary. Journal of Clinical Endocrinology and Metabolism, v. 35, p. 443–447, 1982. DOI: 10.1210/jcem-35-3-443.

15. CELEC, P.; et al. Salivary sex hormones during the menstrual cycle. Endocrine Journal, v. 56, n. 3, p. 521–523, 2009. DOI: 10.1507/endocrj.k08e-334.

16. GANDARA, B. K.; LERESCHE, L.; MANCL, L. Patterns of salivary estradiol and progesterone across the menstrual cycle. Annals of the New York Academy of Sciences, v. 1098, p. 446–450, 2007. DOI: 10.1196/annals.1384.030.

17. BAIRD, D. T. Ovarian steroid secretion and metabolism in women. In: JAMES, V. H. T.; SERIO, M.; GIUSTI, G. (Eds.). The Endocrine Function of the Human Ovary. New York: Academic Press, 1976. p. 125–133.

18. McNATTY, K. P.; et al. Concentration of estrogens and androgens in human ovarian venous plasma and follicular fluid throughout the menstrual cycle. Journal of Endocrinology, v. 71, p. 77–85, 1976. DOI: 10.1677/joe.0.0710077.

19. GRUHN, J. G.; KAZER, R. R. Hormonal Regulation of the Menstrual Cycle: The Evolution of Concepts. New York: Springer, 2013. ISBN 978-1-4899-3496-3.

20. MARCH, C. M.; et al. Roles of estradiol and progesterone in eliciting mid-cycle luteinizing hormone and follicle-stimulating hormone surges. Journal of Clinical Endocrinology and Metabolism, v. 49, p. 507–512, 1979. DOI: 10.1210/jcem-49-4-507.

21. STRICKER, R.; et al. Establishment of detailed reference values for luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clinical Chemistry and Laboratory Medicine, v. 44, n. 7, p. 883–887, 2006. DOI: 10.1515/CCLM.2006.160.

22. SIMPSON, E. R.; McDONALD, P. C. Endocrinology of pregnancy. In: WILLIAMS, R. H. (Ed.). Textbook of Endocrinology. Philadelphia: W. B. Saunders Company, 1981. p. 412–422.

23. LIPSON, S. F.; ELLISON, P. T. Comparison of salivary steroid profiles in naturally occurring conception and non-conception cycles. Human Reproduction, v. 11, n. 10, p. 2090–2096, 1996. DOI: 10.1093/oxfordjournals.humrep.a019085.

24. CHOE, J. K.; KHAN-DAWOOD, F. S.; DAWOOD, M. Y. Progesterone and estradiol in saliva and plasma during the menstrual cycle. American Journal of Obstetrics and Gynecology, v. 147, n. 5, p. 557–562, 1983. DOI: 10.1016/0002-9378(83)90073-2.

25. LEWIS, J. G. Steroid analysis in saliva: an overview. Clinical Biochemist Reviews, v. 27, p. 139–146, 2006. PMID: 17078775.

26. GAMEIRO, C. M.; ROMÃO, F.; CASTELO-BRANCO, C. Menopause and aging: changes in the immune system – a review. Maturitas, v. 67, n. 4, p. 316–320, 2010. DOI: 10.1016/j.maturitas.2010.08.003.

Estrona na Saliva

1. RESNIK, R.; KILLAM, A. P.; BATTAGLIA, F. C.; et al. The stimulation of uterine blood flow by various estrogens. Endocrinology, v. 94, p. 1192–1198, 1974. DOI: 10.1210/endo-94-4-1192. PMID: 4810226.

2. FAYMAN, C.; WINTER, J. S. D.; REYES, F. I. Patterns of gonadotropins and gonadal steroids throughout life. Clinical Obstetrics and Gynecology, v. 3, p. 467–483, 1976. DOI: 10.1097/00003081-197609000-00007.

3. BAIRD, D. T.; FRASER, I. S. Blood production and ovarian secretion rates of estradiol-17β and estrone in women throughout the menstrual cycle. Journal of Clinical Endocrinology and Metabolism, v. 38, p. 1009–1017, 1974. DOI: 10.1210/jcem-38-6-1009. PMID: 4597337.

4. LINDBERG, B. S.; JOHANSSON, E. D. B.; NILSSON, B. A. Plasma levels of non-conjugated oestrone, oestradiol-17β and oestriol during uncomplicated pregnancy. Acta Obstetricia et Gynecologica Scandinavica, v. 32, p. 21–29, 1974. DOI: 10.3109/00016347409158091. PMID: 4840814.

5. DRAFTA, D.; SCHINDLER, A. E.; STROE, E. W.; NEACSU, E. Age-related changes of plasma steroids in normal adult males. Journal of Steroid Biochemistry, v. 17, p. 683–687, 1982. DOI: 10.1016/0022-4731(82)90229-9. PMID: 7128831.

6. DEVANE, G. W.; CZEKALA, N. M.; JUDD, H. L.; YEN, S. S. C. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. American Journal of Obstetrics and Gynecology, v. 121, p. 496–500, 1975. DOI: 10.1016/0002-9378(75)90573-8. PMID: 1091823.

Progesterona na Saliva

1. MILLER, W. L. Molecular biology of steroid hormone synthesis. Endocrine Reviews, v. 9, n. 3, p. 295–318, 1988. DOI: 10.1210/edrv-9-3-295. PMID: 3061784.

2. FILICORI, M.; BUTLER, J. P.; CROWLEY, W. F. Jr. Neuroendocrine regulation of the corpus luteum in the human. Journal of Clinical Investigation, v. 73, n. 6, p. 1638–1647, 1984. DOI: 10.1172/JCI111363. PMID: 6427839.

3. CSAPÓ, A. I.; PULKKINEN, M. O.; WIEST, W. G. Effects of lutectomy and progesterone replacement therapy in early pregnancy patients. American Journal of Obstetrics and Gynecology, v. 115, n. 6, p. 759–765, 1973. DOI: 10.1016/0002-9378(73)90553-3. PMID: 4701756.

4. HENSON, M. C. Pregnancy maintenance and the regulation of placental progesterone biosynthesis in the baboon. Human Reproduction Update, v. 4, n. 4, p. 389–405, 1998. DOI: 10.1093/humupd/4.4.389. PMID: 9825857.

Testosterona na Saliva

1. WEST, C. D.; et al. Simultaneous measurement of multiple plasma steroids by radioimmunoassay demonstrating episodic secretion. Journal of Clinical Endocrinology and Metabolism, v. 36, n. 6, p. 1230–1236, 1973. DOI: 10.1210/jcem-36-6-1230.

2. BUTLER, G. E.; et al. Salivary testosterone levels and the progress of puberty in the normal boy. Clinical Endocrinology, v. 30, p. 587–596, 1989. DOI: 10.1111/j.1365-2265.1989.tb00453.x.

3. OSREDKAR, J.; et al. Salivary free testosterone in hirsutism. Annals of Clinical Biochemistry, v. 26, p. 522–526, 1989. DOI: 10.1177/000456328902600511.

4. DABBS, J. M.; et al. Reliability of salivary testosterone measurements: a multicenter evaluation. Clinical Chemistry, v. 41, n. 11, p. 1581–1584, 1995. PMID: 7497635.

5. VALERO-POLITI, J.; FUENTES-ARDERIU, X. Daily rhythmic and non-rhythmic variations of LH, FSH, SHBG, and testosterone in men. European Journal of Clinical Chemistry and Clinical Biochemistry, v. 34, p. 455–462, 1996. DOI: 10.1515/cclm.1996.34.6.455.

6. ROSNER, W. An extraordinarily inaccurate assay for free testosterone is still with us. Journal of Clinical Endocrinology and Metabolism, v. 86, n. 6, p. 2903, 2001. DOI: 10.1210/jcem.86.6.7582.

7. MILLER, K. K.; et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. Journal of Clinical Endocrinology and Metabolism, v. 89, n. 2, p. 525–533, 2004. DOI: 10.1210/jc.2003-031287.

8. STANCZYK, F. Z.; et al. Limitations of direct estradiol and testosterone immunoassay kits. Steroids, v. 68, p. 1173–1178, 2003. DOI: 10.1016/j.steroids.2003.08.009.

9. TAIEB, J.; et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography–mass spectrometry in sera from 116 men, women, and children. Clinical Chemistry, v. 49, n. 8, p. 1381–1395, 2003. DOI: 10.1373/49.8.1381.

10. STERZER, P.; et al. Intentional updating in episodic memory: low testosterone associates with enhanced memory updating. Neuroendocrinology Letters, v. 36, n. 3, p. 269–273, 2015. PMID: 26122292.

11. LEWIS, J. G. Steroid analysis in saliva: an overview. Clinical Biochemist Reviews, v. 27, p. 139–146, 2006. PMID: 17078775.

12. MORLEY, J. E.; et al. Validation of salivary testosterone as a screening test for male hypogonadism. The Aging Male, v. 9, p. 165–169, 2006. DOI: 10.1080/13685530600841863.

13. ROSNER, W.; et al. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. Journal of Clinical Endocrinology and Metabolism, v. 92, n. 2, p. 405–413, 2007. DOI: 10.1210/jc.2006-1864.

14. YASUDA, M.; et al. Low testosterone level of middle-aged Japanese men – the association between low testosterone levels and quality of life. Journal of Men’s Health and Gender, v. 4, n. 2, p. 149–155, 2007. DOI: 10.1016/S1571-8913(07)80060-2.

15. KREBS, A.; et al. Evaluating the four most important salivary sex steroids during male puberty: testosterone best characterizes pubertal development. Journal of Pediatric Endocrinology and Metabolism, v. 32, n. 3, p. 287–294, 2019. DOI: 10.1515/jpem-2018-0387.

16. REIMERS, L.; DIEKHOF, E. K. Testosterone is associated with cooperation during intergroup competition by enhancing parochial altruism. Frontiers in Neuroscience, v. 9, art. 183, 2015. DOI: 10.3389/fnins.2015.00183.

17. MARKS, V. False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries. Clinical Chemistry, v. 48, n. 11, p. 2008–2016, 2002. PMID: 12406973.

18. TATE, J.; WARD, G. Interferences in immunoassays. Clinical Biochemist Reviews, v. 25, p. 105–120, maio 2004. PMID: 18458713.

19. SELBY, C. Interference in immunoassays. Annals of Clinical Biochemistry, v. 36, p. 704–721, 1999. DOI: 10.1177/000456329903600603. PMID: 10672372.

17-OH Progesterona na Saliva

1. CHROUSOS, G. P.; LORIAUX, D. L.; MANN, D. L.; et al. Late onset 21-hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease. Annals of Internal Medicine, v. 96, p. 143–148, 1982. DOI: 10.7326/0003-4819-96-2-143. PMID: 6278301.

2. MEIKLE, A. W.; WORLEY, R. J.; WEST, C. D. Adrenal corticoid hyper-response in hirsute women. Fertility and Sterility, v. 41, p. 575–581, 1984. DOI: 10.1016/S0015-0282(16)47845-2. PMID: 6697231.

3. BUSTLER, J. E.; CHANG, R. J.; PRESTON, D. L.; et al. Interrelationships of circulating maternal steroids: progesterone, 16α-hydroxyprogesterone, 17α-hydroxyprogesterone, 20α-hydroxyprogesterone, and Δ5-pregnenolone. Journal of Clinical Endocrinology and Metabolism, v. 48, p. 133–138, 1979. DOI: 10.1210/jcem-48-1-133. PMID: 218672.

4. URBAN, M. D.; LEE, P. A.; MIGNON, C. J. Adult high infertility in men with congenital adrenalized hyperplasia. New England Journal of Medicine, v. 299, p. 1392–1396, 1978. DOI: 10.1056/NEJM197812212992504. PMID: 736526.

5. ZERAH, M.; PANG, S.; NEW, M. Morning salivary 17-hydroxyprogesterone is a useful screening test for nonclassical 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, v. 65, n. 2, p. 227–233, 1987. DOI: 10.1210/jcem-65-2-227. PMID: 3610589.

6. OTTEN, B. J.; et al. Salivary, plasma androstenedione and 17-hydroxyprogesterone levels in congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, v. 57, n. 5, p. 1169–1172, 1983. DOI: 10.1210/jcem-57-5-1169. PMID: 6418308.

7. WALKER, R. F.; et al. Radioimmunoassay of 17-hydroxyprogesterone in saliva, parotid fluid, and plasma of congenital adrenal hyperplasia patients. Clinical Chemistry, v. 25, n. 4, p. 542–545, 1979. PMID: 428250.

Referências Técnicas & Científicas

Quality Management System for Medical Devices
ISO 13485:2016
ISO 9001:2015

Laboratório Associado
Sociedade Brasileira de
Análises Clínicas

Referências Técnicas & Científicas

Quality Management System for Medical Devices ISO 13485:2016 ISO 9001:2015

Laboratório Associado Sociedade Brasileira de Análises Clínicas

Quality Management System for Medical Devices
ISO 13485:2016
ISO 9001:2015

Laboratório Associado
Sociedade Brasileira de
Análises Clínicas